WO2009149253A2 - Mrna cap analogs - Google Patents
Mrna cap analogs Download PDFInfo
- Publication number
- WO2009149253A2 WO2009149253A2 PCT/US2009/046249 US2009046249W WO2009149253A2 WO 2009149253 A2 WO2009149253 A2 WO 2009149253A2 US 2009046249 W US2009046249 W US 2009046249W WO 2009149253 A2 WO2009149253 A2 WO 2009149253A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- recited
- composition
- rna
- rna molecule
- protein
- Prior art date
Links
- 108020004999 messenger RNA Proteins 0.000 title abstract description 71
- 238000013519 translation Methods 0.000 claims abstract description 46
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 39
- 238000000338 in vitro Methods 0.000 claims abstract description 34
- 238000001727 in vivo Methods 0.000 claims abstract description 20
- 239000000203 mixture Substances 0.000 claims description 76
- 238000000034 method Methods 0.000 claims description 59
- 229910052739 hydrogen Inorganic materials 0.000 claims description 53
- 230000014616 translation Effects 0.000 claims description 50
- 102000004169 proteins and genes Human genes 0.000 claims description 32
- 108090000623 proteins and genes Proteins 0.000 claims description 32
- 108700026244 Open Reading Frames Proteins 0.000 claims description 25
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 25
- -1 methylenenaphthyl Chemical group 0.000 claims description 17
- 150000001875 compounds Chemical class 0.000 claims description 16
- 238000013518 transcription Methods 0.000 claims description 13
- 230000035897 transcription Effects 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 12
- 230000002194 synthesizing effect Effects 0.000 claims description 12
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims description 10
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims description 10
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 10
- 210000004748 cultured cell Anatomy 0.000 claims description 9
- 229910052711 selenium Inorganic materials 0.000 claims description 9
- 108091033319 polynucleotide Proteins 0.000 claims description 8
- 102000040430 polynucleotide Human genes 0.000 claims description 8
- 239000002157 polynucleotide Substances 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 238000001243 protein synthesis Methods 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- LQRJAEQXMSMEDP-XCHBZYMASA-N peptide a Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)NCCCC[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C/C=1C=CC=CC=1)C(N)=O)C(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C\C1=CC=CC=C1 LQRJAEQXMSMEDP-XCHBZYMASA-N 0.000 claims description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 201000003639 autosomal recessive cerebellar ataxia Diseases 0.000 abstract description 12
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 11
- 239000003112 inhibitor Substances 0.000 abstract description 8
- 238000002360 preparation method Methods 0.000 abstract description 8
- JRPHGDYSKGJTKZ-UHFFFAOYSA-N selenophosphoric acid Chemical group OP(O)([SeH])=O JRPHGDYSKGJTKZ-UHFFFAOYSA-N 0.000 abstract description 8
- 230000001419 dependent effect Effects 0.000 abstract description 6
- 229910019142 PO4 Inorganic materials 0.000 abstract description 4
- 239000010452 phosphate Substances 0.000 abstract description 4
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 abstract description 4
- 101100014154 Arabidopsis thaliana RACK1A gene Proteins 0.000 abstract 1
- 241001421757 Arcas Species 0.000 abstract 1
- 229910000085 borane Inorganic materials 0.000 description 110
- 229920002477 rna polymer Polymers 0.000 description 58
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 37
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 35
- 239000000047 product Substances 0.000 description 33
- 230000015572 biosynthetic process Effects 0.000 description 32
- 239000005089 Luciferase Substances 0.000 description 31
- 238000003786 synthesis reaction Methods 0.000 description 31
- 108060001084 Luciferase Proteins 0.000 description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 239000000243 solution Substances 0.000 description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
- 238000006243 chemical reaction Methods 0.000 description 28
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 27
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 26
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 22
- 229910001868 water Inorganic materials 0.000 description 22
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 20
- 239000011541 reaction mixture Substances 0.000 description 20
- 238000005160 1H NMR spectroscopy Methods 0.000 description 17
- 238000004679 31P NMR spectroscopy Methods 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 17
- 239000011669 selenium Substances 0.000 description 16
- AFQIYTIJXGTIEY-UHFFFAOYSA-N hydrogen carbonate;triethylazanium Chemical compound OC(O)=O.CCN(CC)CC AFQIYTIJXGTIEY-UHFFFAOYSA-N 0.000 description 15
- JRPHGDYSKGJTKZ-UHFFFAOYSA-K selenophosphate Chemical compound [O-]P([O-])([O-])=[Se] JRPHGDYSKGJTKZ-UHFFFAOYSA-K 0.000 description 15
- 229920005654 Sephadex Polymers 0.000 description 14
- 239000012507 Sephadex™ Substances 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 13
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 13
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 239000001226 triphosphate Substances 0.000 description 12
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 11
- 229940029575 guanosine Drugs 0.000 description 11
- 159000000000 sodium salts Chemical class 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 235000011178 triphosphate Nutrition 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 101150087322 DCPS gene Proteins 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 9
- 101100386724 Schizosaccharomyces pombe (strain 972 / ATCC 24843) nhm1 gene Proteins 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- XKMLYUALXHKNFT-UHFFFAOYSA-N rGTP Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O XKMLYUALXHKNFT-UHFFFAOYSA-N 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- 239000002777 nucleoside Substances 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 238000012512 characterization method Methods 0.000 description 7
- 230000007062 hydrolysis Effects 0.000 description 7
- 238000006460 hydrolysis reaction Methods 0.000 description 7
- 150000007928 imidazolide derivatives Chemical class 0.000 description 7
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 7
- 239000006166 lysate Substances 0.000 description 7
- 230000003287 optical effect Effects 0.000 description 7
- 210000001995 reticulocyte Anatomy 0.000 description 7
- 238000004007 reversed phase HPLC Methods 0.000 description 7
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical group [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 238000011894 semi-preparative HPLC Methods 0.000 description 6
- 108090000331 Firefly luciferases Proteins 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 238000004255 ion exchange chromatography Methods 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 4
- 229920000388 Polyphosphate Polymers 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000002349 favourable effect Effects 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 150000003833 nucleoside derivatives Chemical class 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 4
- 239000001205 polyphosphate Substances 0.000 description 4
- 235000011176 polyphosphates Nutrition 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 239000003161 ribonuclease inhibitor Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- VMZOBROUFBEGAR-UHFFFAOYSA-N tris(trimethylsilyl) phosphite Chemical compound C[Si](C)(C)OP(O[Si](C)(C)C)O[Si](C)(C)C VMZOBROUFBEGAR-UHFFFAOYSA-N 0.000 description 4
- 208000005623 Carcinogenesis Diseases 0.000 description 3
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 3
- OVBJJZOQPCKUOR-UHFFFAOYSA-L EDTA disodium salt dihydrate Chemical compound O.O.[Na+].[Na+].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O OVBJJZOQPCKUOR-UHFFFAOYSA-L 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 101000819572 Mus musculus Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 108091036407 Polyadenylation Proteins 0.000 description 3
- 101710141795 Ribonuclease inhibitor Proteins 0.000 description 3
- 229940122208 Ribonuclease inhibitor Drugs 0.000 description 3
- 102100037968 Ribonuclease inhibitor Human genes 0.000 description 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- TVYLOQJEHUAACN-UHFFFAOYSA-N bis(trimethylsilyl) hydrogen phosphite Chemical compound C[Si](C)(C)OP(O)O[Si](C)(C)C TVYLOQJEHUAACN-UHFFFAOYSA-N 0.000 description 3
- 238000006664 bond formation reaction Methods 0.000 description 3
- 230000036952 cancer formation Effects 0.000 description 3
- 231100000504 carcinogenesis Toxicity 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 3
- 235000013928 guanylic acid Nutrition 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- LULXBAGMGMJJRW-UHFFFAOYSA-N n,2-bis(trimethylsilyl)acetamide Chemical compound C[Si](C)(C)CC(=O)N[Si](C)(C)C LULXBAGMGMJJRW-UHFFFAOYSA-N 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 3
- FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 2
- CJRPFMAFZQADLD-IOSLPCCCSA-O 2-amino-9-[(2r,3r,4r,5r)-4-hydroxy-5-(hydroxymethyl)-3-methoxyoxolan-2-yl]-7-methyl-3h-purin-9-ium-6-one Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1[N+]1=CN(C)C2=C1NC(N)=NC2=O CJRPFMAFZQADLD-IOSLPCCCSA-O 0.000 description 2
- 108020003589 5' Untranslated Regions Proteins 0.000 description 2
- OGHAROSJZRTIOK-KQYNXXCUSA-O 7-methylguanosine Chemical compound C1=2N=C(N)NC(=O)C=2[N+](C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OGHAROSJZRTIOK-KQYNXXCUSA-O 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 2
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 2
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 2
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 102000009609 Pyrophosphatases Human genes 0.000 description 2
- 108010009413 Pyrophosphatases Proteins 0.000 description 2
- 108091000106 RNA cap binding Proteins 0.000 description 2
- 102000028391 RNA cap binding Human genes 0.000 description 2
- 108010065868 RNA polymerase SP6 Proteins 0.000 description 2
- 102000039471 Small Nuclear RNA Human genes 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- SIOVKLKJSOKLIF-UHFFFAOYSA-N bis(trimethylsilyl)acetamide Chemical compound C[Si](C)(C)OC(C)=N[Si](C)(C)C SIOVKLKJSOKLIF-UHFFFAOYSA-N 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000002050 diffraction method Methods 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000007515 enzymatic degradation Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 108091029842 small nuclear ribonucleic acid Proteins 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- HNTAOTWBCIFHIR-KQYNXXCUSA-O 2-amino-9-[(2R,3R,4S,5R)-5-(dihydroxyphosphinoselenoyloxymethyl)-3,4-dihydroxyoxolan-2-yl]-7-methyl-1H-purin-9-ium-6-one Chemical compound P(O)(O)(=[Se])OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=[N+](C)C=2C(=O)NC(N)=NC1=2)O)O HNTAOTWBCIFHIR-KQYNXXCUSA-O 0.000 description 1
- DQXKJYLSEHMASX-MCDZGGTQSA-N 2-amino-9-[(2R,3R,4S,5R)-5-(dioxidophosphinoselenoyloxymethyl)-3,4-dihydroxyoxolan-2-yl]-7-methyl-1H-purin-9-ium-6-one triethylazanium Chemical compound C(C)[NH+](CC)CC.P([O-])([O-])(=[Se])OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=[N+](C=2C(=O)NC(N)=NC12)C)O)O DQXKJYLSEHMASX-MCDZGGTQSA-N 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- 125000001417 5'-guanylyl group Chemical group C=12N=C(N([H])[H])N([H])C(=O)C=1N=C([H])N2[C@@]1([H])[C@@](O[H])([H])[C@@](O[H])([H])[C@](C(OP(=O)(O[H])[*])([H])[H])([H])O1 0.000 description 1
- 101150100998 Ace gene Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 241000180579 Arca Species 0.000 description 1
- 241000244186 Ascaris Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- KGQZICWZJFINKK-IOSLPCCCSA-N C[N+]1=CN([C@@H]([C@@H]2OC)O[C@H](COP([O-])([Se]P(O)(O)=O)=O)[C@H]2O)C(N=C(N)N2)=C1C2=O Chemical compound C[N+]1=CN([C@@H]([C@@H]2OC)O[C@H](COP([O-])([Se]P(O)(O)=O)=O)[C@H]2O)C(N=C(N)N2)=C1C2=O KGQZICWZJFINKK-IOSLPCCCSA-N 0.000 description 1
- UUWJNBOCAPUTBK-UHFFFAOYSA-N C[n]1c(N=C(N)NC2=O)c2nc1 Chemical compound C[n]1c(N=C(N)NC2=O)c2nc1 UUWJNBOCAPUTBK-UHFFFAOYSA-N 0.000 description 1
- 101100223333 Caenorhabditis elegans dcap-2 gene Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102100022466 Eukaryotic translation initiation factor 4E-binding protein 1 Human genes 0.000 description 1
- 108050000946 Eukaryotic translation initiation factor 4E-binding protein 1 Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000871498 Homo sapiens m7GpppX diphosphatase Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 108010059724 Micrococcal Nuclease Proteins 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000002298 Purinergic P2Y Receptors Human genes 0.000 description 1
- 108010000818 Purinergic P2Y Receptors Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- DDCNFXKMBXJODA-GWTDSMLYSA-N [(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate 1H-imidazole Chemical class C1=CNC=N1.C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O DDCNFXKMBXJODA-GWTDSMLYSA-N 0.000 description 1
- FHHZHGZBHYYWTG-INFSMZHSSA-N [(2r,3s,4r,5r)-5-(2-amino-7-methyl-6-oxo-3h-purin-9-ium-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl [[[(2r,3s,4r,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] phosphate Chemical compound N1C(N)=NC(=O)C2=C1[N+]([C@H]1[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=C(C(N=C(N)N4)=O)N=C3)O)O1)O)=CN2C FHHZHGZBHYYWTG-INFSMZHSSA-N 0.000 description 1
- HETSHOUSYUCGPQ-MCDZGGTQSA-O [N-]1C=NC=C1.C[N+]1=CN([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)C=2N=C(NC(C12)=O)N Chemical class [N-]1C=NC=C1.C[N+]1=CN([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)C=2N=C(NC(C12)=O)N HETSHOUSYUCGPQ-MCDZGGTQSA-O 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine group Chemical group [C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C=NC=2C(N)=NC=NC12 OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 238000010504 bond cleavage reaction Methods 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 108091092330 cytoplasmic RNA Proteins 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000003297 denaturating effect Effects 0.000 description 1
- 238000005828 desilylation reaction Methods 0.000 description 1
- VPRCZJANGAJOFU-UHFFFAOYSA-N dihydroxy-selanylidene-trimethylsilyloxy-lambda5-phosphane Chemical compound C[Si](C)(C)OP(O)(O)=[Se] VPRCZJANGAJOFU-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- MWEQTWJABOLLOS-UHFFFAOYSA-L disodium;[[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-oxidophosphoryl] hydrogen phosphate;trihydrate Chemical compound O.O.O.[Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP([O-])(=O)OP(O)([O-])=O)C(O)C1O MWEQTWJABOLLOS-UHFFFAOYSA-L 0.000 description 1
- IIRVGTWONXBBAW-UHFFFAOYSA-M disodium;dioxido(oxo)phosphanium Chemical compound [Na+].[Na+].[O-][P+]([O-])=O IIRVGTWONXBBAW-UHFFFAOYSA-M 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 102000050769 human DcpS Human genes 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910001510 metal chloride Inorganic materials 0.000 description 1
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- IIWVFLOQEJCOIX-UHFFFAOYSA-N oxathiaphospholane Chemical compound C1CPSO1 IIWVFLOQEJCOIX-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 238000001394 phosphorus-31 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-O tributylazanium Chemical compound CCCC[NH+](CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-O 0.000 description 1
- WVLBCYQITXONBZ-UHFFFAOYSA-N trimethyl phosphate Chemical compound COP(=O)(OC)OC WVLBCYQITXONBZ-UHFFFAOYSA-N 0.000 description 1
- SIOVKLKJSOKLIF-HJWRWDBZSA-N trimethylsilyl (1z)-n-trimethylsilylethanimidate Chemical compound C[Si](C)(C)OC(/C)=N\[Si](C)(C)C SIOVKLKJSOKLIF-HJWRWDBZSA-N 0.000 description 1
- SYUQQUMHOZQROL-UHFFFAOYSA-N trimethylsilyl dihydrogen phosphite Chemical compound C[Si](C)(C)OP(O)O SYUQQUMHOZQROL-UHFFFAOYSA-N 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
Definitions
- This invention pertains to new dinucleotide cap analogs and their uses, RNA molecules containing these analogs, the use of these analogs in RNA synthesis, the use of these analogs in peptide and protein synthesis, the use of these analogs to inhibit translation, and other uses.
- RNA Ribonucleic acid
- RNA Ribonucleic acid
- mRNA messenger RNA
- mRNA messenger RNA
- the cap contains a 5'-5' triphosphate linkage between two nucleosides and a 7-methyl group on a guanine ring distal to the RNA polymer chain.
- Some other forms of RNA are also capped, e.g., small nuclear RNAs (snRNAs). RNA capping regulates intracellular molecular activities, including RNA stability and translational efficiency.
- capped RNA molecules are useful because it allows one to prepare RNA molecules that will function properly in a variety of biological applications. Such applications include both research applications and commercial production of polypeptides, e.g., producing in a cell-free translation system polypeptides containing an "unnatural" amino acid at a specific site, or producing in cultured cells polypeptides that require post-translational modification for activity or stability. Because capped RNA molecules are more stable and bind more readily to the cell's translational machinery, translation of capped RNAs proceeds for a considerably longer time than is the case for non-capped RNAs, resulting in greater production of protein.
- RNA polymerase initiates transcription with a nucleophilic attack by the 3'-OH of the Guo moiety of m 7 GpppG on the ⁇ -phosphate of the next templated nucleoside triphosphate, resulting in the intermediate m 7 GpppGpN.
- the formation of the competing GTP-initiated product pppGpN is suppressed by setting the molar ratio of m 7 GpppG to GTP between 5 and 10 in the transcription reaction mixture.
- the 5'- capped mRNAs produced with m 7 GpppG can take either of two forms, one containing the cap analog incorporated in the correct, forward orientation [m 7 G(5')ppp(5')GpNp...], and one containing the analog in the reverse orientation [G(5')ppp(5')m 7 GpNp...]. The latter are not recognized as capped mRNAs by the cell's translational machinery and decrease the translational efficiency of synthetic mRNA preparations.
- RNA transcripts are incorporated into RNA transcripts exclusively in the forward orientation and are therefore called “anti-reverse cap analogs” (ARCAs).
- ARCA-capped mRNAs had translational efficiencies that were two-fold higher than transcripts capped with m 7 GpppG (Stepinski et ai., 2001 ).
- mRNAs capped with ARCAs are translated 2- to 2.5-fold more efficiently than those capped with m 7 GpppG. See E. Grudzien et ai., "Differential inhibition of mRNA degradation pathways by novel cap analogs," J. Biol. Chem., vol. 281 , pp. 1857-1867 (2006).
- the amount of protein produced from synthetic mRNAs introduced into cultured mammalian cells is limited by the natural degradation of mRNA.
- One in vivo pathway for mRNA degradation begins with the removal of the mRNA cap. This removal is catalyzed by a heterodimeric pyrophosphatase, which contains a regulatory subunit (Dcp1 ) and a catalytic subunit (Dcp2).
- the catalytic subunit cleaves between the ⁇ and ⁇ phosphate groups of the triphosphate bridge.
- mRNA capped with m 2 7 ' 3 O Gppc H2 pG had lower overall translational efficiency, presumably because m 2 7 ' 3'" °Gppc H2 pG has a lower binding affinity for elF4E than that of m 2 7 ' 3 O GpppG.
- the eukaryotic translation initiation factor elF4E is involved in bringing the capped mRNA to the ribosome for translation.
- RNA, vol. 13, pp. 1745-1755 showed that mRNAs capped with S-ARCAs modified at the ⁇ phosphate were resistant to hydrolysis by recombinant human Dcp2 in vitro. Furthermore, mRNA capped with one ⁇ S- ARCA diastereomer had a longer half-life when introduced into mammalian cells than that of the corresponding ARCA-capped mRNA; and it also had a greater translational efficiency in cells. The first of these properties presumably resulted from the resistance of the ⁇ S-ARCA to hydrolysis by Dcp2, and the second property presumably resulted from the higher affinity of the ⁇ -S-ARCA for elF4E.
- mRNA cap analogs Another use for synthetic mRNA cap analogs is to inhibit cap- dependent translation by competition with capped mRNA for binding to elF4E. See A. Cai et al., "Quantitative assessment of mRNA cap analogues as inhibitors of in vitro translation," Biochemistry, vol. 38, pp. 8538-8547 (1999); and E. Grudzien et al., “Novel cap analogs for in vitro synthesis of mRNAs with high translational efficiency," RNA, vol. 10, pp. 1479-1487 (2004).
- cap analogs to inhibit translation has potential therapeutic significance.
- Many types of cancer cells overexpress elF4E, which can lead to increased expression of proteins that promote oncogenesis and metastasis.
- elF4E overexpresses elF4E
- Reducing elF4E expression with siRNA, antisense oligonucleotides, or a specific elF4E repressor can inhibit tumor growth and oncogenesis.
- J. R. Graff et al. "Therapeutic suppression of translation initiation factor elF4E expression reduces tumor growth without toxicity” J.
- cap analogs are specific inhibitors of elF4E activity and are therefore potentially useful as agents for treating oncogenesis and metastasis, immunosuppression in organ transplantation, and other medical conditions.
- these potential uses for cap analogs have never previously been demonstrated in vivo, in part due to the instability of cap analogs in intracellular conditions.
- a boranophosphate modification in which one of the non- bridging O atoms is replaced with a borane group (BH 3 ) (sometimes called the BH 3 - analogs).
- a phosphoroselenoate modification in which one of the non- bridging O atoms is replaced with a selenium atom (sometimes called the Se-analogs).
- the phosphorothioate, boranophosphate, and phosphoroselenoate groups all replace non- bridging oxygen atoms and share some chemical and biochemical properties. However, there are also differences among these groups.
- the P-X bond lengths differ (where X denotes S, Se, or BH 3 ), the van der Waals radii of the X groups differ, and the affinity of the X groups for various divalent and other metal cations differ.
- X denotes S, Se, or BH 3
- the van der Waals radii of the X groups differ
- the affinity of the X groups for various divalent and other metal cations differ.
- Boranophosphate polyphosphate dinucleoside analogs are described in published patent application US2006/0287271 , as are their use against diseases modulated by P2Y receptors, e.g., type 2 diabetes and cancer.
- Boranophosphate nucleotide analogs have similarities with phosphorothioate analogs due to similar bond angles, pK a values, and P- diastereoisomerism. However, in some cases they are as much as 10-fold more resistant to enzymatic hydrolysis than their phosphorothioate counterparts. They are also more lipophilic than phosphorothioates, which may help them to penetrate cell membranes and reach intracellular translational machinery. Boranophosphate analogs can also be used in boron neutron capture therapy (BNCT). See B. R. Shaw et al., "Reading, Writing and Modulating Genetic Information with Boranophosphate Mimics of Nucleotides, DNA and RNA," Ann. N.Y.
- Phosphoroselenoate nucleotide analogs are similar to phosphorothioates and boranophosphates due to their similar bond angles, pK a values, P- diastereoisomerism, and resistance to enzymatic degradation.
- Phosphoroselenoates can be very useful in nucleic acid crystallography because Se can be used in the multi-wavelength anomalous dispersion (MAD) technique.
- MAD multi-wavelength anomalous dispersion
- the novel dinucleotide cap analogs are modified at various phosphate positions with a boranophosphate group or a phosphoroselenoate group.
- the novel analogs have broad utility as reagents in the preparation of capped mRNAs. They have increased stability both in vitro and in vivo. They may be used as inhibitors of cap-dependent translation.
- the boranophosphate or phosphoroselenoate group has a 2'-0 or 3'-O-alkyl group, preferably a methyl group, producing analogs called BH 3 -ARCAs or Se-ARCAs.
- ARCAs may be modified with ⁇ -, ⁇ -, or ⁇ -boranophosphate or phosphoroselenoate groups. Selection of the type and location of modification modulates the activity of proteins that recognize the cap during synthesis, processing, nucleo-cytoplasmic export, translation, and degradation of mRNA.
- Table 1 lists several BH 3 -analogs and Se-analogs that have been or will be synthesized and characterized by chemical, biophysical, biochemical, and molecular biological methods.
- Compounds that are particularly favorable in mRNA caps include the ⁇ - BH 3 -ARCAs and ⁇ -Se-ARCAs.
- Compounds that are particularly favorable as translation inhibitors include the ⁇ - and y- BH 3 -analogs and ⁇ -Se-analogs.
- Fig. 1 depicts a synthesis of cap analogs with a boranophosphate group at the ⁇ -position of the 5',5'-triphosphate bridge.
- Fig. 2 depicts a synthesis of cap analogs with a boranophosphate group at the ⁇ -position of the 5',5'-triphosphate bridge.
- Fig. 3 depicts a synthesis of m 7 Gpp BH3 pm 7 G (method II).
- FIG. 4 depicts a synthesis of m 2 7i2' 0 Gpp BH3 pG.
- Fig. 5 depicts a synthesis of m 2 7i2' °Gpp Se PG.
- Fig. 6 depicts a synthesis of m 7 Gp Se ppG.
- Fig. 7 depicts relative in vitro translational efficiencies of firefly luciferase mRNAs capped with ApppG (non-functional cap analog), m 7 GpppG, m 2 7 ' 3'" °GpppG, the boranophosphate cap analogs m 7 Gpp BH3 pG (diastereomeric 1 :1 mixture), and m 7 Gpp B H3pm 7 G.
- Fig. 8 depicts the inhibition of in vitro luciferase mRNA translation by boranophosphate cap analogs.
- Fig. 9 depicts inhibition of in vitro luciferase mRNA translation by boranophosphate cap analogs incubated in rabbit reticulocyte lysate for 60 min before the start of translation.
- FIG. 10 depicts in vitro translational efficiencies of firefly luciferase mRNAs capped with ApppG, m 7 GpppG, m 2 7 ' 3' °GpppG, and the phosphoroselenoate cap analogs m 2 7 2' °Gpp Se PG (D1 ) and (D2).
- Fig. 11 depicts inhibition of in vitro luciferase mRNA translation by phosphoroselenoate cap analogs.
- Fig. 12 depicts inhibition of in vitro luciferase mRNA translation by phosphoroselenoate cap analogs incubated in rabbit reticulocyte lysate for 60 min before the start of translation.
- Fig. 13 depicts relative in vitro translational efficiencies of firefly luciferase mRNAs bearing A 31 poly-A tail, 5'-capped with various analogs.
- Fig. 14 depicts measurements of the stability of luciferase mRNAs capped with various analogs and having a 60-base poly(A) tail in cultured HeLa cells following nucleoporation.
- Fig. 15 depicts the translational efficiency of luciferase mRNAs capped with various analogs and bearing a 60-nt poly(A) tail in cultured HeLa cells following nucleoporation.
- a mononucleotide is converted to a reactive imidazolide derivative, which is then coupled to another mononucleotide in DMF in the presence of excess ZnCI 2 .
- the ZnCI 2 significantly enhances the solubility of the reactants in organic solvents, inhibits hydrolysis of imidazolide derivatives, and accelerates the reaction rate.
- Other metal chlorides such as MnCI 2 , CdCI 2 or MgCI 2 may also be used to mediate pyrophosphate bond formation, but are generally less efficient than ZnCI 2 . See M.
- Fig. 1 depicts the synthesis of analogs modified at the ⁇ -position.
- Guanosine 5'-(H-phosphonate) was silated with N, O- bis(trimethylsilyl)acetamide (BSA).
- BSA bis(trimethylsilyl)acetamide
- the resulting intermediate, bis(trimethylsilyl)phosphite was boronated by treatment with a BH 3 « SMe 2 complex, without isolation.
- Subsequent desilylation and purification by ion-exchange chromatography afforded the desired guanosine 5'-boranophosphate at -30% yield.
- guanosine 5'-boranophosphate was coupled with the imidazolide derivative of m 7 GDP or of m 2 7 ' 2 O GDP, respectively, in a 9:1 DMF/water mixture in the presence of excess MgCI 2 .
- the result was a mixture of two P- diastereomers that were then separated by reverse phase (RP) HPLC.
- the diastereomers were termed D1 and D2, accordingly to their elution order from the RP HPLC column.
- Fig. 2 depicts the synthesis of analogs modified at the ⁇ -position.
- the boranophosphate triethylammonium salt was obtained by a modification of the procedure of V. Nahum et al., "Boranophosphate salts as an excellent mimic of phosphate salts: preparation, characterization, and properties," Eur. J. Inorg. Chem., vol. 20, pp. 4124-4131 (2004).
- tris(trimethylsilyl) phosphite was boronated with the BH 3 « SMe 2 complex.
- This compound was subsequently treated with methyl iodide in DMSO to introduce a methyl group at the guanosine N7 position.
- the reaction produced a mixture of monomethylated and dimethylated cap analogs (m 7 Gpp BH3 pG and m 7 Gpp BH3 pm 7 G).
- the ratio of these products can be controlled by adjusting the reaction conditions.
- m 7 Gpp BH3 pG was formed as a major product (-70% yield).
- m 7 Gpp BH3 pm 7 G was the predominant product (-50%).
- a preferred route to the latter product was to couple boranophosphate with a 7-methylguanosine imidazolide derivative, which allowed us to isolate the product with 34% yield, but in a one-step synthesis. See Fig. 3.
- Fig. 5 depicts the synthesis of m 2 7 ' 2 O Gpp Se PG The selenophosphate
- This compound was coupled with the imidazolide derivative of 7,2'-O- dimethylguanosine 5'-monophosphate (m 2 7 ' 2 O GMP-lm) to give 7,2'-O-dimethylguanosine 5'- O-(2-selenodiphoshpate) (m 2 7 ' 2 O GDP ⁇ Se).
- Anhydrous ZnCI 2 was used to mediate the coupling reaction; the ZnCI 2 dramatically increased the solubility of the reagents in DMF, and also accelerated the reaction rate. The reaction was very rapid; essentially 100% conversion of m 2 7 ' 2'" °GMP-lm into m 2 7 2' ⁇ °GDP ⁇ Se was observed by RP HPLC after 15 min.
- the m 2 7 ' 2'" °GDP ⁇ Se was unstable in acidic aqueous solutions (being hydrolyzed to m 2 7 ' 2 0 GMP), and only moderately stable in neutral or basic solutions. Thus, care was taken to maintain the pH at 7 or above during purification of m 2 7 ' 2 O GDP ⁇ Se, which allowed the product to be isolated with 80% yield after ion-exchange chromatography. The m 2 7i2 O GDP ⁇ Se was then coupled with the imidazolide derivative of GMP in the presence of excess ZnCI 2 .
- the products were characterized by mass spectrometry, 1 H NMR, and 31 P NMR to confirm structures and homogeneity.
- the D1 and D2 isomers of m 2 7i2 O Gpp Se PG were stable in aqueous solution, did not undergo appreciable hydrolysis or oxidation, and could be stored as solids, protected from moisture at -20° C, for at least three months.
- Example 1 General procedures for isolation and characterization of cap analogs. Intermediate nucleotides were separated by ion-exchange chromatography on a DEAE-Sephadex A-25 column (HCO 3 ' form) with a linear gradient of triethylammonium bicarbonate (TEAB) in deionized water. After evaporation under reduced pressure with addition of ethanol, the intermediates were isolated as triethylammonium salts. Final products (the cap analogs) were further separated by semi-preparative RP HPLC and, after repeated freeze-drying, were isolated as ammonium salts.
- TEAB triethylammonium bicarbonate
- Analytical HPLC was performed on an Agilent Technologies 1200 Series apparatus, using a Supelcosil LC-18-T RP column (4.6 x 250 mm, flow rate 1.3 ml/min) with a linear gradient of 0%-25% methanol in 0.05 M ammonium acetate buffer (pH 5.9). Eluting compounds were detected with a UV-Vis detector (at 260 nm), and a fluorescence detector (excitation at 280 nm and emission at 337 nm).
- Example 2 General procedure for synthesis of nucleotide imidazolide derivatives. GMP-Im, m 2 7 2'" °GMP-lm, GDP-Im, and m 2 7 2'" °GDP-lm were prepared as described by T. Mukaiyama et al., "Phosphorylation by oxidation-reduction condensation. Preparation of active phosphorylating reagents," M. Bull. Chem. Soc. Jpn., vol. 44, p. 2284 (1971 ).
- the nucleotide (1 equiv., TEA salt), imidazole (8 equiv.), and 2,2'- dithiodipyridine (3 equiv.) were mixed in DMF (-2.5 ml/100 mg of nucleotide).
- Triethylamine (2 equiv.) and triphenylphosphine (3 equiv.) were added, and the mixture was stirred for 6-8 h.
- the product was precipitated from the reaction mixture with a solution of anhydrous NaCIO 4 (1 equiv. per negative charge) in dry acetone ( ⁇ 8 ml per ml of DMF). After cooling at 4° C, the precipitate was filtered, washed repeatedly with cold, dry acetone, and dried in vacuum over P 4 Oi 0 . Yields were 80%-100%.
- the reaction mixture was diluted with water (80 ml), adjusted to pH -1.5 with solid NaHCO 3 and heated to 70 0 C for 1 h.
- the solution was allowed to cool to room temperature, adjusted to pH ⁇ 6 with NaHCO 3 , diluted with 80 ml of water, and subjected to chromatography on DEAE Sephadex with a 0-0.9 M gradient of TEAB. Fractions eluting at 0.6-0.65 M TEAB and containing -3.0 mmol of product were collected, evaporated, and dried in a vacuum dessicator over P 2 O 5 . This produced 1.34 g of guanosine 5'-(H-phosphonate) triethylammonium salt (yield 75%).
- Example 4 Guanosine 5'-O-boranophosphate, triethylammonium salt. Guanosine 5'-(H-phosphonate) (1.03 g, 2.3 mmol) was placed in a round-bottom flask and suspended in 30 ml of dry acetonitrile. The flask was sealed with a rubber septum and flushed with argon for 30 min. N,O-bistrimethylsilylacetamide (11.3 ml, 46 mmol) was injected through a syringe, and the mixture was vigorously stirred until a clear solution was obtained, and was then stirred for an additional 30 min.
- N,O-bistrimethylsilylacetamide (11.3 ml, 46 mmol) was injected through a syringe, and the mixture was vigorously stirred until a clear solution was obtained, and was then stirred for an additional 30 min.
- Example 5 Synthesis of m 7 Gppp BH3 G. To a mixture of GMPBH 3 (50 mg, 0.089 mmol, TEA salt) and m 7 GDP-lm (100 mg, 0.18 mmol, sodium salt) in 2.5 ml of DMF/H 2 O (9:1 ) was added anhydrous MgCI 2 (110 mg, 1.16 mmol) portionwise, and the mixture was vigorously shaken until all reagents were dissolved. The solution was stirred at RT for 3 days, and then the reaction was quenched by addition of EDTA (430 mg, 1.16 mmol) in 25 ml of water with pH adjusted to ⁇ 6 by addition of solid NaHCO 3 .
- GMPBH 3 50 mg, 0.089 mmol, TEA salt
- m 7 GDP-lm 100 mg, 0.18 mmol, sodium salt
- Example 6 m 2 7 ' 2'"0 Gppp BH3 G. To a mixture of GMPBH 3 (30 mg, 0.053 mmol, TEA salt) and m 2 7 ' 2 " °GDP-lm (60 mg, 0.11 mmol, sodium salt) in 1.5 ml of DMF/H 2 O (9:1 ) was added anhydrous MgCI 2 (80 mg, 0.85 mmol) portionwise, and the mixture was vigorously shaken until all reagents were dissolved.
- GMPBH 3 30 mg, 0.053 mmol, TEA salt
- m 2 7 ' 2 " °GDP-lm 60 mg, 0.11 mmol, sodium salt
- Example 7 Boranophosphate triethylammonium salt. This salt was prepared by a modification of the procedure of V. Nahum et ai, "Boranophosphate Salts as an Excellent Mimic of Phosphate Salts: Preparation, Characterization, and Properties," J. Inorg. Chem. vol. 20, pp. 4124-4131 (2004). Tris(trimethylsilyl)phosphite (600 ⁇ l, 1.8 mmol) was added to a round-bottom flask containing 5 ml dry acetonitrile. The flask was sealed with a rubber septum and flushed with argon for 30 min.
- N,O-bistrimethylsilylacetamide (1.5 ml, 5.4 mmol) was injected through a syringe. After 30 min., the solution was cooled in an ice-bath, and a 2 M solution of BH 3 « SMe 2 complex in THF (1.35 ml) was added. After 5 min, the flask was removed from the ice bath, and stirring continued for 30 min. The solution was then evaporated under reduced pressure to an oily residue, placed again in the ice bath, treated with 20 ml of methanol and 0.5 ml of triethylamine, and was then stirred for 2 h at room temperature. The solution was evaporated to dryness, and the residue was dried over P 2 O 5 .
- Example 9 m 7 Gpp BH3 pG.
- Gpp BH3 pG 35 mg, TEA salt
- DMSO DMSO
- 20 ⁇ l of methyl iodide were added.
- the reaction was quenched by addition of 15 ml water, and the pH was adjusted to ⁇ 7 with solid NaHCO 3 .
- Products were separated on DEAE Sephadex with a 0-1.2 M gradient of TEAB.
- a diastereomeric mixture of m 7 Gpp BH3 pG (550 optical density units) was collected and the solvent was evaporated. The product was then dissolved in a small amount of water and converted to the sodium salt on Dowex resin.
- Diastereomers were subsequently resolved by semi-preparative HPLC, and freeze-dried three times. Yields after HPLC separation were 10.2 mg of m 7 Gpp BH3 pG (D1 ) and 9.8 mg of m 7 Gpp BH3 pG (D2) as NH 4 + salts (37.2 % and 35.6 %, respectively).
- ESI MS (-) m/z:799.13 (calc. for C 21 H 31 N 10 O 17 P 3 B: 799.12).
- Example 10 m 7 Gpp BH3 pm 7 G (Method I).
- Gpp BH3 pG 50 mg, 800 optical density units, TEA salt
- DMSO 1.0 ml of DMSO
- 30 ⁇ l of methyl iodide were added.
- an additional 30 ⁇ l of methyl iodide were added.
- the reaction was quenched by adding 15 ml water and adjusted to pH ⁇ 7 with solid NaHCO 3 .
- Products were separated on DEAE Sephadex with a 0-1.2 M gradient of TEAB.
- m 7 GppeH3pm 7 G 200 optical units density was collected, evaporated, and converted into the sodium salt on Dowex resin.
- Example 11 m 7 Gpp B H3pm 7 G (Method II).
- ITi 7 GMP-Im imidazolide derivative of ITi 7 GMP
- boranophosphate triethylammonium salt 75 mg, 0.25 mmol, sodium salt
- Example 12 m 2 7 ' 2 °Gpp BH3 pG.
- m 2 7i2 O GMP-lm 15 mg, 0.03 mmol, sodium salt
- boranophosphate triethylammonium salt 30 mg, 0.1 mmol
- anhydrous MgCI 2 40 mg, 0.4 mmol
- GMP-Im 40 mg, 0.09 mmol
- MgCI 2 40 mg
- Example 13 Selenophosphate triethylammonium salt.
- a suspension of selenium (160 mg, 2 mmol) in pyridine (1 ml) was added dropwise through a syringe into a septum-sealed and argon-bubbled solution of tris(trimethylsilyl) phosphite (600 ⁇ l, 1.8 mmol) in dry CH 3 CN (20 ml). The resulting solution was held at room temperature for 30 min, and was then evaporated to dryness. Then a solution of triethylamine (500 ⁇ l, 3.6 mmol) in MeOH (20 ml) was added, and the mixture was stirred at room temperature for 2 h. The solvent was removed under reduced pressure and the residue re-evaporated twice with methanol. The product, which was obtained as an oily, yellowish residue, was used without further treatment in the following reaction:
- Example 14 7,2'-O-dimethylguanosine 5'-O-(2- selenodiphosphate) (m 2 7 ' 2 °GDP ⁇ Se).
- Example 15 m 2 7 ' 2 "0 Gpps ⁇ pG. m 2 72' °GDP ⁇ Se (250 mg, 0.35 mmol) and GMP-Im (250 mg, 0.50 mmol) were suspended in 5 ml of DMF, and anhydrous ZnCI 2 (480 mg, 3.5 mmol) was added. The resulting solution was kept at room temperature for 2 days. The reaction was quenched by adding disodium EDTA (1.3 g, 3.5 mmol) in 100 ml of water, and neutralized with solid NaHCO 3 . Products were isolated on DEAE Sephadex with a 0-1.2 M gradient of TEAB.
- Example 16 7-methylguanosine 5'-O-(H-phosphonate).
- guanosine 5'-O-(H-phosphonate) 260 mg, 0.65 mmol
- DMSO DMSO
- methyl iodide 322 ⁇ l, 5.2 mmol
- the reaction was quenched by diluting with 200 ml of water, and the reaction mixture was extracted three times with ether. The remaining ether was removed from the aqueous layer under reduced pressure, and the product was isolated on DEAE Sephadex with a 0- 0.7 M gradient of TEAB.
- Example 18 m 7 Gp Se ppG. To a suspension of m 7 GMPSe (10 mg,
- Example 19 Measuring binding affinities to elF4E. Fluorescence titration measurements were carried out on an LS-50B or LS-55 spectrofluorometer (Perkin Elmer Co.) at 20.0 ⁇ 0.2 0 C in 50 mM HEPES/KOH (pH 7.2), 0.5 mM EDTA, and 1 mM DTT, with ionic strength adjusted to 150 mM by addition of KCI. Various cap analogue solutions, of increasing concentration, were added in 1 ⁇ l aliquots to 1.4 ml of 0.1 or 0.2 ⁇ M protein solutions.
- the concentration of protein was allowed to be a free parameter in the equilibrium equation, to determine the amount of "active" protein.
- Example 20 Assay of susceptibility to DcpS.
- Human DcpS was expressed in Escherichia coli as described in L. Cohen et ai, "Nematode m 7 GpppG and m 3 2i2i7 GpppG decapping: activities in Ascaris embryos and characterization of C. elegans scavenger DcpS," RNA, vol. 10, pp. 1609-1624 (2004).
- a 15 ⁇ M solution of the protein in 20 mM Tris buffer, pH 7.5, containing 50 mM KCI, 0.2 mM EDTA, 1 mM DTT, 0.5 mM PMSF, and 20% glycerol was stored at -8O 0 C until used. Enzymatic reactions were carried out at 3O 0 C in 500 ⁇ l of 50 mM Tris-HCI, pH 7.9, containing 20 mM MgCI 2 and 60 mM (NH 4 ) 2 SO 4 . A 40 ⁇ M solution of the selected cap analog was treated with 5.0 ⁇ l of DcpS for 120 min.
- Example 21 Synthesis of mRNAs capped with BH 3 and Se- analogs.
- Method I for analogs m 7 Gpp B H3pG (D1/D2 mix) and m 7 Gpp B H3pm 7 G.
- a DNA template for in vitro transcription was synthesized by PCR from the plasmid SP6p-5'UTR ⁇ - globin-LUCiferase. The template contained the SP6 promoter followed by the 5'-UTR sequence of rabbit ⁇ -globin mRNA and the entire firefly luciferase mRNA coding region.
- a typical in vitro transcription reaction mixture (50 ⁇ l) contained SP6 transcription buffer (Fermentas, cat. no.
- EP0131 2 ⁇ g of DNA template, 2 U/ ⁇ l RiboLock Ribonuclease Inhibitor (Fermentas), 2 mM each of ATP, CTP, and UTP, 0.1 mM GTP, and 1 mM dinucleotide cap analog.
- the reaction mixture was incubated at 37 0 C for 5 min before the addition of SP6 RNA polymerase (Fermentas) to a final concentration of 2 U/ ⁇ l. After 30 min of incubation at 37 0 C, GTP was added to a final concentration of 1 mM, and the reaction continued for an additional 90 min.
- RNA transcripts were purified on DEPC-treated Sephadex G-50 spin columns (Pharmacia). The integrity of transcripts was confirmed by electrophoresis on a non-denaturating, 1 % agarose gel. Concentrations were determined spectrophotometrically. The transcripts were stored at - 80 0 C until used.
- Example 21 Synthesis of mRNAs capped with BH 3 and Se- analogs.
- Method Il for analogs m 2 7 ' 2' 0 Gpp BH3 pG (D1 ), m 2 7 ' 2' 0 Gpp BH3 pG (D2), m 2 7 2'" 0 GpPP BH3 G (D1), m 2 7 ' 2 ' 0 GPPP BH3 G (D2), m 2 7 2' °Gpp Se PG (D1),and m 2 7 2' °Gpp Se PG (D2), m 7 Gpp BH3 pG (D1), m 7 Gpp BH3 pm 7 G, m 2 72'"0 Gpp s pG (D1) and m 2 7 2'"0 Gpp s pG (D2)).
- polyadenylated luciferase mRNAs were synthesized in vitro by PCR from a dsDNA template that contained the SP6 promoter, the 5'-UTR sequence of rabbit ⁇ -globin mRNA, the entire firefly luciferase coding region, and 31 adenosine residues.
- a typical transcription reaction mixture (40 ⁇ l) contained SP6 transcription buffer (Fermentas), 0.7 ug of DNA template, 1 U/ ⁇ l RiboLock Ribonuclease Inhibitor (Fermentas), 0.5 mM each of ATP, CTP, and UTP, 0.1 mM GTP, and 0.5 mM dinucleotide cap analog.
- the reaction mixture was incubated at 37 0 C for 5 min before addition of SP6 RNA polymerase (Fermentas) to a final concentration of 1 U/ ⁇ l, and incubation then continued for 45 min at 37 0 C.
- the reaction mixture was treated with DNase as in Method I.
- RNA transcripts were purified with NucAway Spin Columns (Ambion). The integrity of transcripts and quantitation was performed as in Method I.
- Example 22 Translation efficiency of capped mRNAs in an in vitro system.
- a micrococcal nuclease-treated rabbit reticulocyte lysate system (Flexi Rabbit Reticulocyte Lysate System, Promega) was used for in vitro translation. Translation reactions were performed in 10 ⁇ l for 60 min at 30 0 C.
- a typical reaction mixture contained 40% reticulocyte lysate, the 20 "standard" amino acids (0.01 mM each), MgCI 2 (1.2 mM) , potassium acetate (170 mM), and mRNA (five different concentrations of each transcript, ranging from 0.25 to 4 ⁇ g/ml).
- Luciferase activity was measured in a luminometer (Glomax, Promega). Linear regression was used to fit the data points (luciferase activity versus concentration of mRNA transcript), and translational efficiency was defined as the slope of this line. The relative translational efficiencies of the test mRNAs were compared to that of m 7 GpppG-capped luciferase mRNA, the latter being defined as 1.0.
- BH 3 -analogs In vitro translation reactions were performed in 12.5 ⁇ l for 60 min at 30 0 C under conditions favorable for cap-dependent translation. In some cases, the reaction mixture was incubated for 60 min at 30°C prior to adding the dinucleotide cap analog (inhibitor) and m 2 7 ' 3 O GpppG-capped luciferase mRNA to start translation. In other cases, to analyze biological stability, the cap analog was incubated in the translation mixture for 60 min at 30 0 C prior to adding the luciferase mRNA to start translation.
- a typical reaction mixture contained 56% reticulocyte lysate, the 20 "standard” amino acids (0.01 mM each), MgCI 2 (1.2 mM) , potassium acetate (170 mM), RiboLock Ribonuclease Inhibitor (0.32 U/ ⁇ l), cap analog solution (1/10 of total reaction volume), and m 2 7 3 O GpppG-capped luciferase RNA.
- the transcript was not polyadenylated, but instead had a 59-base 3'-UTR. Reactions were performed with cap analog concentrations ranging from 0.12 to 100 ⁇ M. Luciferase activity was measured in a luminometer.
- IC 50 values defined as the concentration of cap analog that resulted in 50% inhibition.
- the data are presented in Table 2.
- Example 24 Results of biophysical and biochemical characterization of BH 3 - and Se- analogs.
- the binding affinities of eukaryotic elF4E for various cap analogs were determined by fluorescence quenching. This biophysical test allows one to predict the potential efficacy of cap analogs in translation. Those having higher affinities for elF4E than the unmodified cap analog (m 7 GpppG) are expected to be better recognized by the translational machinery, leading to higher translational efficiencies. They also are expected to compete more effectively with unmodified mRNA when free cap dinucleotides are used to inhibit translation. See generally E.
- Example 25 Translational efficiencies of mRNAs capped with
- Example 26 Susceptibility of the new analogs to degradation by
- DcpS was also determined. Unexpectedly, it was found that all ⁇ -BH 3 -analogs were resistant to hydrolysis by DcpS (Table 2). Since J. Kowalska et al. (2008) showed that the corresponding ⁇ -phosphorothioate cap analogs were all susceptible to DcpS, this result indicates that different phosphate modifications at the same position of the triphosphate bridge can have different biochemical consequences. For Se-analogs, by contrast, only those modified in the Y position were resistant to DcpS (Table 3).
- Example 27 The BH 3 -analogs as inhibitors of in vitro cap- dependent translation.
- Two type of experiments were carried out. In one set of experiments (condition A), a cap analog was added to the translation system together with luciferase mRNA. In the other set of experiments (condition B), the cap analog was incubated in the translation system for 60 min before addition of mRNA.
- condition A a cap analog was added to the translation system together with luciferase mRNA.
- condition B the cap analog was incubated in the translation system for 60 min before addition of mRNA.
- BH 3 - and Se-analogs were found to be strong inhibitors of translation (Tables 2 and 3).
- incubation of some of these analogs did not impair their inhibitory properties, which is presumably a reflection of their resistance to pyrophosphatase attack.
- DcpS the stability of analogs in the translation system.
- Example 28 Measurement of translational efficiency and mRNA decay in cultured HeLa cells. Nucleoporation was used to deliver RNA into HeLa cells with a Nucleofector Il (Amaxa Biosystems), following the manufacture's recommended protocols. One microgram of RNA was introduced into 10 6 cells in Nucleofector Solution V, using program T-024.
- RNAs were further purified using the RNeasy ® mini kit and analyzed by real-time PCR.
- Reverse transcription was performed on 400 ng of RNA in 20- ⁇ l reaction mixtures containing 5.5 mM MgCI 2 , 500 ⁇ M of each dNTP, 2.5 ⁇ M random hexamers, 0.2 units of RNase inhibitor, and 0.8 units of MultiScribe reverse transcriptase (Applied Biosystems). Reaction mixtures were incubated at 25°C for 10 min, 48°C for 30 min, and 95°C for 5 min. Quantitative real-time PCR was performed with specific primers designed for each mRNA with the Beacon Designer tool (Bio-Rad). Luciferase mRNA levels were determined by PCR using primers designed to amplify bases 226-398 from the 5' end.
- Mouse GAPDH mRNA levels were determined (as control) by the same method and in the same RNA samples using primers specific for mouse GAPDH. Amplification and detection were performed with the iCycler IQ real time PCR detection system in 25- ⁇ l reaction mixtures containing 5 ⁇ l of the transcription reaction mixture (50 ng of cDNA), 12.5 ⁇ l of IQ SYBRgreen Supermix, and 0.3 mM primers (Bio-Rad). The incubation conditions were 3 min at 95 0 C for polymerase activation, followed by 40 cycles, each of 15 s at 95 0 C and 1 min at 60 0 C. Luciferase mRNA levels were calculated using the absolute standard curve method as described in User Bulletin No.
- Luciferase mRNA was then normalized by comparison to the measured level of mouse GAPDH mRNA in each sample, which was an indicator of total cellular RNA purified from a cell extract. Luciferase mRNA remaining at each time point was converted to a percent of the RNA present at zero time, and the results were plotted as logio([RNA]) versus time to determine ty 2 . Results are presented in Figure 14.
- compositions and methods within the scope of the present invention include, but are not limited to, the following:
- a composition comprising one or more of the following compounds, or a stereoisomer of one or more of the following compounds, or mixtures of stereoisomers of one or more of the following compounds, or a salt or salts of any of them:
- Y 1 , Y 2 , Y 3 , and Y 4 are selected from the group consisting of O, BH 3 , and Se; the various Y, groups may be the same or different, wherein / is 1 , 2, 3, or 4; and at least one Y, is BH 3 or Se;
- n 0 or 1 ;
- R is selected from the group consisting of:
- R3 and R4 are selected from the group consisting of H, OH, OCH 3 and OCH 2 CH 3 ; and R3 and R4 may be the same or different; is selected from the group consisting of
- R1 and R2 are selected from the group consisting of H, OH, OCH 3 , or OCH 2 CH 3 ; and R1 and R2 may be the same or different; and
- X is selected from the group consisting of methyl, ethyl, propyl, butyl, benzyl, substituted benzyl, methylenenaphthyl, and substituted methylenenaphthyl.
- RNA molecule whose 5' end incorporates a composition as described.
- a method of synthesizing, in vitro or in vivo, an RNA molecule as described comprising reacting ATP, CTP, UTP, and GTP, a composition as described, and polynucleotide template in the presence of RNA polymerase, under conditions conductive to transcription by the RNA polymerase of the polynucleotide template into an RNA copy; whereby some of the RNA copies will incorporate the composition to make an RNA molecule as described.
- a method for synthesizing a protein or peptide in vitro comprising translating an RNA molecule as described in a cell-free protein synthesis system, wherein the RNA molecule comprises an open reading frame, under conditions conductive to translating the open reading frame of the RNA molecule into the protein or peptide encoded by the open reading frame.
- a method for synthesizing a protein or peptide in vivo or in cultured cells comprising translating an RNA molecule as described in vivo or in cultured cells, wherein the RNA molecule comprises an open reading frame, under conditions conductive to translating the open reading frame of the RNA molecule into the protein or peptide encoded by the open reading frame.
- a method comprising administering to a system that translates RNA into protein or peptide a composition as described, wherein the amount of the composition administered is effective to wholly or partially inhibit the translation of RNA into protein or peptide.
- R1 and R2 are not both OH.
- R4 is OH; n is 0; Yi is O; Y 2 is Se; Y 3 is O; W is
- RNA molecule whose 5' end incorporates a composition as described.
- a method of synthesizing, in vitro or in vivo, an RNA molecule as described comprising reacting ATP, CTP, UTP, and GTP, a composition as recited, and polynucleotide template in the presence of RNA polymerase, under conditions conductive to transcription by the RNA polymerase of the polynucleotide template into an RNA copy; whereby some of the RNA copies will incorporate the composition to make an RNA molecule as described.
- a method for synthesizing a protein or peptide in vitro comprising translating an RNA molecule as described in a cell-free protein synthesis system, wherein the RNA molecule comprises an open reading frame, under conditions conductive to translating the open reading frame of the RNA molecule into the protein or peptide encoded by the open reading frame.
- a method for synthesizing a protein or peptide in vivo or in cultured cells comprising translating an RNA molecule as described in vivo or in cultured cells, wherein the RNA molecule comprises an open reading frame, under conditions conductive to translating the open reading frame of the RNA molecule into the protein or peptide encoded by the open reading frame.
- a method comprising administering to a system that translates RNA into protein or peptide a composition as described, wherein the amount of the composition administered is effective to wholly or partially inhibit the translation of RNA into protein or peptide.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011512643A JP5715560B2 (en) | 2008-06-06 | 2009-06-04 | mRNA CAP analogs |
AU2009256131A AU2009256131B2 (en) | 2008-06-06 | 2009-06-04 | mRNA cap analogs |
US12/996,243 US8519110B2 (en) | 2008-06-06 | 2009-06-04 | mRNA cap analogs |
PL09759412T PL2297175T3 (en) | 2008-06-06 | 2009-06-04 | Mrna cap analogs |
EP09759412.1A EP2297175B1 (en) | 2008-06-06 | 2009-06-04 | Mrna cap analogs |
CA2727091A CA2727091C (en) | 2008-06-06 | 2009-06-04 | Mrna cap analogs |
ES09759412T ES2425781T3 (en) | 2008-06-06 | 2009-06-04 | MRNA CAP analogues |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL385388A PL215513B1 (en) | 2008-06-06 | 2008-06-06 | New borane phosphate analogs of dinucleotides, their application, RNA particle, method of obtaining RNA and method of obtaining peptides or protein |
PLP385388 | 2008-06-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009149253A2 true WO2009149253A2 (en) | 2009-12-10 |
WO2009149253A3 WO2009149253A3 (en) | 2010-03-25 |
Family
ID=41398862
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/046249 WO2009149253A2 (en) | 2008-06-06 | 2009-06-04 | Mrna cap analogs |
Country Status (8)
Country | Link |
---|---|
US (1) | US8519110B2 (en) |
EP (1) | EP2297175B1 (en) |
JP (1) | JP5715560B2 (en) |
AU (1) | AU2009256131B2 (en) |
CA (1) | CA2727091C (en) |
ES (1) | ES2425781T3 (en) |
PL (2) | PL215513B1 (en) |
WO (1) | WO2009149253A2 (en) |
Cited By (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103254260A (en) * | 2013-02-07 | 2013-08-21 | 江西科技师范大学 | Method for synthesizing symmetric dinucleoside diphosphate disodium salt from nucleoside hydrogen phosphite monoester |
US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
WO2014152211A1 (en) | 2013-03-14 | 2014-09-25 | Moderna Therapeutics, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
WO2014152540A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
WO2015034928A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
US8999380B2 (en) | 2012-04-02 | 2015-04-07 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
WO2015051214A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
WO2015101416A1 (en) | 2013-12-30 | 2015-07-09 | Curevac Gmbh | Methods for rna analysis |
US9107886B2 (en) | 2012-04-02 | 2015-08-18 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding basic helix-loop-helix family member E41 |
WO2015188933A1 (en) | 2014-06-10 | 2015-12-17 | Curevac Ag | Methods and means for enhancing rna production |
US9271996B2 (en) | 2011-12-16 | 2016-03-01 | Moderna Therapeutics, Inc. | Formulation and delivery of PLGA microspheres |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9334328B2 (en) | 2010-10-01 | 2016-05-10 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
WO2016098028A1 (en) | 2014-12-16 | 2016-06-23 | Novartis Ag | End capped nucleic acid molecules |
US9428535B2 (en) | 2011-10-03 | 2016-08-30 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
WO2016170176A1 (en) | 2015-04-22 | 2016-10-27 | Curevac Ag | Rna containing composition for treatment of tumor diseases |
EP2971033A4 (en) * | 2013-03-15 | 2016-11-16 | Moderna Therapeutics Inc | Manufacturing methods for production of rna transcripts |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9597380B2 (en) | 2012-11-26 | 2017-03-21 | Modernatx, Inc. | Terminally modified RNA |
WO2017066781A1 (en) * | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Mrna cap analogs with modified phosphate linkage |
WO2017066789A1 (en) * | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Mrna cap analogs with modified sugar |
WO2017109161A1 (en) | 2015-12-23 | 2017-06-29 | Curevac Ag | Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof |
WO2017130151A1 (en) * | 2016-01-29 | 2017-08-03 | Uniwersytet Warszawski | 5'-phosphorothiolate mrna 5'-end (cap) analogs, mrna comprising the same, method of obtaining and uses thereof |
WO2017140345A1 (en) | 2016-02-15 | 2017-08-24 | Curevac Ag | Method for analyzing by-products of rna in vitro transcription |
WO2017149139A1 (en) | 2016-03-03 | 2017-09-08 | Curevac Ag | Rna analysis by total hydrolysis |
WO2017162461A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Trans-replicating rna |
WO2018033254A2 (en) | 2016-08-19 | 2018-02-22 | Curevac Ag | Rna for cancer therapy |
US9950068B2 (en) | 2011-03-31 | 2018-04-24 | Modernatx, Inc. | Delivery and formulation of engineered nucleic acids |
WO2018078053A1 (en) | 2016-10-26 | 2018-05-03 | Curevac Ag | Lipid nanoparticle mrna vaccines |
WO2018115507A2 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Henipavirus vaccine |
WO2018115527A2 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Mers coronavirus vaccine |
US10077439B2 (en) | 2013-03-15 | 2018-09-18 | Modernatx, Inc. | Removal of DNA fragments in mRNA production process |
WO2018236617A1 (en) | 2017-06-21 | 2018-12-27 | New England Biolabs, Inc. | Use of thermostable rna polymerases to produce rnas having reduced immunogenicity |
EP3424524A2 (en) | 2017-07-04 | 2019-01-09 | CureVac AG | Cancer rna-vaccine |
WO2019038332A1 (en) | 2017-08-22 | 2019-02-28 | Curevac Ag | Bunyavirales vaccine |
WO2019053003A1 (en) | 2017-09-13 | 2019-03-21 | Biontech Rna Pharmaceuticals Gmbh | Method of enhancing rna expression in a cell |
WO2019053012A1 (en) | 2017-09-13 | 2019-03-21 | Biontech Rna Pharmaceuticals Gmbh | Rna replicon for reprogramming somatic cells |
WO2019053056A1 (en) | 2017-09-13 | 2019-03-21 | Biontech Cell & Gene Therapies Gmbh | Rna replicon for expressing a t cell receptor or an artificial t cell receptor |
US10286086B2 (en) | 2014-06-19 | 2019-05-14 | Modernatx, Inc. | Alternative nucleic acid molecules and uses thereof |
WO2019092153A1 (en) | 2017-11-08 | 2019-05-16 | Curevac Ag | Rna sequence adaptation |
WO2019115635A1 (en) | 2017-12-13 | 2019-06-20 | Curevac Ag | Flavivirus vaccine |
WO2019122371A1 (en) | 2017-12-21 | 2019-06-27 | Curevac Ag | Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna |
US10385088B2 (en) | 2013-10-02 | 2019-08-20 | Modernatx, Inc. | Polynucleotide molecules and uses thereof |
US10407683B2 (en) | 2014-07-16 | 2019-09-10 | Modernatx, Inc. | Circular polynucleotides |
EP3540060A1 (en) | 2013-12-30 | 2019-09-18 | CureVac AG | Methods for rna analysis |
WO2019193183A2 (en) | 2018-04-05 | 2019-10-10 | Curevac Ag | Novel yellow fever nucleic acid molecules for vaccination |
WO2020002525A1 (en) | 2018-06-27 | 2020-01-02 | Curevac Ag | Novel lassa virus rna molecules and compositions for vaccination |
US10590161B2 (en) | 2013-03-15 | 2020-03-17 | Modernatx, Inc. | Ion exchange purification of mRNA |
US20200109425A1 (en) * | 2018-10-04 | 2020-04-09 | New England Biolabs, Inc. | Methods and Compositions for Increasing Capping Efficiency of Transcribed RNA |
WO2020072914A1 (en) | 2018-10-04 | 2020-04-09 | New England Biolabs, Inc. | Methods and compositions for increasing capping efficiency of transcribed rna |
WO2020128031A2 (en) | 2018-12-21 | 2020-06-25 | Curevac Ag | Rna for malaria vaccines |
WO2020127959A1 (en) | 2018-12-21 | 2020-06-25 | Curevac Ag | Methods for rna analysis |
WO2020161342A1 (en) | 2019-02-08 | 2020-08-13 | Curevac Ag | Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases |
EP3701959A1 (en) | 2016-03-21 | 2020-09-02 | BioNTech RNA Pharmaceuticals GmbH | Rna replicon for versatile and efficient gene expression |
US10815291B2 (en) | 2013-09-30 | 2020-10-27 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
WO2020254535A1 (en) | 2019-06-18 | 2020-12-24 | Curevac Ag | Rotavirus mrna vaccine |
WO2021028439A1 (en) | 2019-08-14 | 2021-02-18 | Curevac Ag | Rna combinations and compositions with decreased immunostimulatory properties |
US11027025B2 (en) | 2013-07-11 | 2021-06-08 | Modernatx, Inc. | Compositions comprising synthetic polynucleotides encoding CRISPR related proteins and synthetic sgRNAs and methods of use |
WO2021123332A1 (en) | 2019-12-20 | 2021-06-24 | Curevac Ag | Lipid nanoparticles for delivery of nucleic acids |
WO2021156267A1 (en) | 2020-02-04 | 2021-08-12 | Curevac Ag | Coronavirus vaccine |
WO2021239880A1 (en) | 2020-05-29 | 2021-12-02 | Curevac Ag | Nucleic acid based combination vaccines |
WO2021245090A1 (en) | 2020-06-04 | 2021-12-09 | BioNTech SE | Rna replicon for versatile and efficient gene expression |
WO2022023559A1 (en) | 2020-07-31 | 2022-02-03 | Curevac Ag | Nucleic acid encoded antibody mixtures |
WO2022043551A2 (en) | 2020-08-31 | 2022-03-03 | Curevac Ag | Multivalent nucleic acid based coronavirus vaccines |
WO2022122689A1 (en) | 2020-12-09 | 2022-06-16 | BioNTech SE | Rna manufacturing |
WO2022135993A2 (en) | 2020-12-22 | 2022-06-30 | Curevac Ag | Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration |
WO2022137133A1 (en) | 2020-12-22 | 2022-06-30 | Curevac Ag | Rna vaccine against sars-cov-2 variants |
US11377470B2 (en) | 2013-03-15 | 2022-07-05 | Modernatx, Inc. | Ribonucleic acid purification |
WO2022162027A2 (en) | 2021-01-27 | 2022-08-04 | Curevac Ag | Method of reducing the immunostimulatory properties of in vitro transcribed rna |
US11434486B2 (en) | 2015-09-17 | 2022-09-06 | Modernatx, Inc. | Polynucleotides containing a morpholino linker |
WO2022200575A1 (en) | 2021-03-26 | 2022-09-29 | Glaxosmithkline Biologicals Sa | Immunogenic compositions |
WO2022207862A2 (en) | 2021-03-31 | 2022-10-06 | Curevac Ag | Syringes containing pharmaceutical compositions comprising rna |
US11471525B2 (en) | 2020-02-04 | 2022-10-18 | Curevac Ag | Coronavirus vaccine |
WO2022233880A1 (en) | 2021-05-03 | 2022-11-10 | Curevac Ag | Improved nucleic acid sequence for cell type specific expression |
WO2023006999A2 (en) | 2021-07-30 | 2023-02-02 | CureVac SE | Mrnas for treatment or prophylaxis of liver diseases |
WO2023007019A1 (en) | 2021-07-30 | 2023-02-02 | CureVac SE | Cap analogs having an acyclic linker to the guanine derivative nucleobase |
WO2023031392A2 (en) | 2021-09-03 | 2023-03-09 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine |
WO2023031394A1 (en) | 2021-09-03 | 2023-03-09 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids |
EP4159741A1 (en) | 2014-07-16 | 2023-04-05 | ModernaTX, Inc. | Method for producing a chimeric polynucleotide encoding a polypeptide having a triazole-containing internucleotide linkage |
WO2023066874A1 (en) | 2021-10-18 | 2023-04-27 | BioNTech SE | Methods for determining mutations for increasing modified replicable rna function and related compositions and their use |
WO2023066875A1 (en) | 2021-10-18 | 2023-04-27 | BioNTech SE | Modified replicable rna and related compositions and their use |
WO2023139170A1 (en) | 2022-01-21 | 2023-07-27 | BioNTech SE | Analysis of rna molecules using catalytic nucleic acids |
WO2023144330A1 (en) | 2022-01-28 | 2023-08-03 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
EP4227319A1 (en) | 2018-04-17 | 2023-08-16 | CureVac SE | Novel rsv rna molecules and compositions for vaccination |
EP4233898A2 (en) | 2016-05-04 | 2023-08-30 | CureVac SE | Influenza mrna vaccines |
EP4239080A2 (en) | 2015-07-01 | 2023-09-06 | CureVac Manufacturing GmbH | Method for analysis of an rna molecule |
WO2023166425A1 (en) | 2022-03-01 | 2023-09-07 | Crispr Therapeutics Ag | Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions |
WO2023180904A1 (en) | 2022-03-21 | 2023-09-28 | Crispr Therapeutics Ag | Methods and compositions for treating lipoprotein-related diseases |
US11779659B2 (en) | 2020-04-22 | 2023-10-10 | BioNTech SE | RNA constructs and uses thereof |
WO2023213378A1 (en) | 2022-05-02 | 2023-11-09 | BioNTech SE | Replicon compositions and methods of using same for the treatment of diseases |
WO2023227608A1 (en) | 2022-05-25 | 2023-11-30 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
US11834651B2 (en) | 2015-05-29 | 2023-12-05 | CureVac Manufacturing GmbH | Method for producing and purifying RNA, comprising at least one step of tangential flow filtration |
US11866754B2 (en) | 2015-10-16 | 2024-01-09 | Modernatx, Inc. | Trinucleotide mRNA cap analogs |
US11872280B2 (en) | 2020-12-22 | 2024-01-16 | CureVac SE | RNA vaccine against SARS-CoV-2 variants |
US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
WO2024017479A1 (en) | 2022-07-21 | 2024-01-25 | BioNTech SE | Multifunctional cells transiently expressing an immune receptor and one or more cytokines, their use and methods for their production |
US11920148B2 (en) | 2017-02-22 | 2024-03-05 | Crispr Therapeutics Ag | Compositions and methods for gene editing |
DE202023106198U1 (en) | 2022-10-28 | 2024-03-21 | CureVac SE | Nucleic acid-based vaccine |
WO2024056856A1 (en) | 2022-09-15 | 2024-03-21 | BioNTech SE | Systems and compositions comprising trans-amplifying rna vectors with mirna |
WO2024068545A1 (en) | 2022-09-26 | 2024-04-04 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
Families Citing this family (110)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013143555A1 (en) * | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
EP2931319B1 (en) | 2012-12-13 | 2019-08-21 | ModernaTX, Inc. | Modified nucleic acid molecules and uses thereof |
WO2016014846A1 (en) | 2014-07-23 | 2016-01-28 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of intrabodies |
EP3041948B1 (en) | 2014-11-10 | 2019-01-09 | Modernatx, Inc. | Alternative nucleic acid molecules containing reduced uracil content and uses thereof |
EP4019635A1 (en) | 2015-03-25 | 2022-06-29 | Editas Medicine, Inc. | Crispr/cas-related methods, compositions and components |
WO2016183236A1 (en) | 2015-05-11 | 2016-11-17 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating hiv infection and aids |
JP7030522B2 (en) | 2015-05-11 | 2022-03-07 | エディタス・メディシン、インコーポレイテッド | Optimized CRISPR / CAS9 system and method for gene editing in stem cells |
CN116334142A (en) | 2015-06-09 | 2023-06-27 | 爱迪塔斯医药公司 | CRISPR/CAS related methods and compositions for improving transplantation |
EP3350333B1 (en) | 2015-09-17 | 2021-10-27 | ModernaTX, Inc. | Polynucleotides containing a stabilizing tail region |
RS63030B1 (en) | 2015-09-17 | 2022-04-29 | Modernatx Inc | Compounds and compositions for intracellular delivery of therapeutic agents |
AU2016336344A1 (en) | 2015-10-05 | 2018-04-19 | Modernatx, Inc. | Methods for therapeutic administration of messenger ribonucleic acid drugs |
AU2016341919A1 (en) | 2015-10-21 | 2018-04-19 | Editas Medicine, Inc. | CRISPR/CAS-related methods and compositions for treating hepatitis b virus |
CN109312338B (en) | 2015-10-30 | 2022-09-27 | 爱迪塔斯医药公司 | CRISPR/CAS related methods and compositions for treating herpes simplex virus |
JP7114465B2 (en) | 2015-12-22 | 2022-08-08 | モデルナティエックス インコーポレイテッド | Compounds and compositions for intracellular delivery of drugs |
EP3394093B1 (en) | 2015-12-23 | 2022-01-26 | Modernatx, Inc. | Methods of using ox40 ligand encoding polynucleotides |
MA43587A (en) | 2016-01-10 | 2018-11-14 | Modernatx Inc | THERAPEUTIC RNA CODING FOR ANTI-CTLA-4 ANTIBODIES |
WO2017180917A2 (en) | 2016-04-13 | 2017-10-19 | Modernatx, Inc. | Lipid compositions and their uses for intratumoral polynucleotide delivery |
MX2018013445A (en) | 2016-05-06 | 2019-09-09 | Juno Therapeutics Inc | Genetically engineered cells and methods of making the same. |
CA3024917A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Combinations of mrnas encoding immune modulating polypeptides and uses thereof |
WO2017201332A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding acyl-coa dehydrogenase, very long-chain for the treatment of very long-chain acyl-coa dehydrogenase deficiency |
WO2017201346A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria |
US11001861B2 (en) | 2016-05-18 | 2021-05-11 | Modernatx, Inc. | Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1 |
EP3458107B1 (en) | 2016-05-18 | 2024-03-13 | ModernaTX, Inc. | Polynucleotides encoding jagged1 for the treatment of alagille syndrome |
CA3024507A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding .alpha.-galactosidase a for the treatment of fabry disease |
JP7246930B2 (en) | 2016-05-18 | 2023-03-28 | モデルナティエックス インコーポレイテッド | Polynucleotides encoding interleukin-12 (IL12) and uses thereof |
AU2017268396B2 (en) | 2016-05-18 | 2023-05-18 | Modernatx, Inc. | Polynucleotides encoding citrin for the treatment of citrullinemia type 2 |
EP3468537A1 (en) | 2016-06-14 | 2019-04-17 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
SG11201907916TA (en) | 2017-03-15 | 2019-09-27 | Modernatx Inc | Compounds and compositions for intracellular delivery of therapeutic agents |
JP7332478B2 (en) | 2017-03-15 | 2023-08-23 | モデルナティエックス インコーポレイテッド | Lipid nanoparticle formulation |
AU2018270111B2 (en) | 2017-05-18 | 2022-07-14 | Modernatx, Inc. | Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof |
US11485972B2 (en) | 2017-05-18 | 2022-11-01 | Modernatx, Inc. | Modified messenger RNA comprising functional RNA elements |
WO2018232006A1 (en) | 2017-06-14 | 2018-12-20 | Modernatx, Inc. | Polynucleotides encoding coagulation factor viii |
WO2018231990A2 (en) | 2017-06-14 | 2018-12-20 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-coa mutase |
EP3638678A1 (en) | 2017-06-14 | 2020-04-22 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
US20200362382A1 (en) | 2017-08-18 | 2020-11-19 | Modernatx, Inc. | Methods of preparing modified rna |
EP3675817A1 (en) | 2017-08-31 | 2020-07-08 | Modernatx, Inc. | Methods of making lipid nanoparticles |
JP7424976B2 (en) | 2017-11-22 | 2024-01-30 | モダーナティエックス・インコーポレイテッド | Polynucleotide encoding propionyl-CoA carboxylase alpha and beta subunits for the treatment of propionic acidemia |
WO2019104160A2 (en) | 2017-11-22 | 2019-05-31 | Modernatx, Inc. | Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria |
MA50803A (en) | 2017-11-22 | 2020-09-30 | Modernatx Inc | POLYNUCLEOTIDES CODING ORNITHINE TRANSCARBAMYLASE FOR THE TREATMENT OF UREA CYCLE DISORDERS |
US11802146B2 (en) | 2018-01-05 | 2023-10-31 | Modernatx, Inc. | Polynucleotides encoding anti-chikungunya virus antibodies |
EP3773745A1 (en) | 2018-04-11 | 2021-02-17 | ModernaTX, Inc. | Messenger rna comprising functional rna elements |
FR3081169B1 (en) * | 2018-05-15 | 2020-06-19 | Messenger Biopharma | SUBSTITUTION OF THE HAT OF MESSENGER RNAS BY TWO RNA SEQUENCES INTRODUCED AT THEIR 5 'END |
WO2020023390A1 (en) | 2018-07-25 | 2020-01-30 | Modernatx, Inc. | Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders |
US20220110966A1 (en) | 2018-09-02 | 2022-04-14 | Modernatx, Inc. | Polynucleotides encoding very long-chain acyl-coa dehydrogenase for the treatment of very long-chain acyl-coa dehydrogenase deficiency |
MA53608A (en) | 2018-09-13 | 2021-07-21 | Modernatx Inc | POLYNUCLEOTIDES ENCODED FOR THE E1-ALPHA, E1-BETA AND E2 SUBUNITS OF THE BRANCHED-CHAIN ALPHA-KETOACID DEHYDROGENASE COMPLEX FOR THE TREATMENT OF LEUCINOSIS |
WO2020056147A2 (en) | 2018-09-13 | 2020-03-19 | Modernatx, Inc. | Polynucleotides encoding glucose-6-phosphatase for the treatment of glycogen storage disease |
MA53615A (en) | 2018-09-14 | 2021-07-21 | Modernatx Inc | POLYNUCLEOTIDES ENCODED FOR POLYPEPTIDE A1, OF THE URIDINE DIPHOSPHATE GLYCOSYLTRANSFERASE 1 FAMILY, FOR THE TREATMENT OF CRIGLER-NAJJAR SYNDROME |
WO2020061367A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
JP2022501367A (en) | 2018-09-20 | 2022-01-06 | モデルナティエックス インコーポレイテッドModernaTX, Inc. | Preparation of lipid nanoparticles and method for administration thereof |
WO2020069169A1 (en) | 2018-09-27 | 2020-04-02 | Modernatx, Inc. | Polynucleotides encoding arginase 1 for the treatment of arginase deficiency |
KR20210133218A (en) | 2019-01-31 | 2021-11-05 | 모더나티엑스, 인크. | Vortex mixer and associated method, system and apparatus thereof |
AU2020214843A1 (en) | 2019-01-31 | 2021-08-19 | Modernatx, Inc. | Methods of preparing lipid nanoparticles |
US20220370354A1 (en) | 2019-05-08 | 2022-11-24 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia |
EP3965797A1 (en) | 2019-05-08 | 2022-03-16 | AstraZeneca AB | Compositions for skin and wounds and methods of use thereof |
EP3986480A1 (en) | 2019-06-24 | 2022-04-27 | ModernaTX, Inc. | Messenger rna comprising functional rna elements and uses thereof |
US20220251577A1 (en) | 2019-06-24 | 2022-08-11 | Modernatx, Inc. | Endonuclease-resistant messenger rna and uses thereof |
CA3150061A1 (en) | 2019-08-07 | 2021-02-11 | Modernatx, Inc. | Compositions and methods for enhanced delivery of agents |
WO2021076811A1 (en) | 2019-10-15 | 2021-04-22 | Moderna TX, Inc. | Mrnas encoding granulocyte-macrophage colony stimulating factor for treating parkinson's disease |
CN114206827B (en) | 2020-04-09 | 2023-05-23 | 苏州艾博生物科技有限公司 | Lipid nanoparticle compositions |
CN113874507A (en) | 2020-04-09 | 2021-12-31 | 苏州艾博生物科技有限公司 | Nucleic acid vaccine for coronavirus |
CA3182920A1 (en) | 2020-05-14 | 2021-11-18 | Modernatx, Inc. | Lnp compositions comprising an mrna therapeutic and an effector molecule |
EP4157217A1 (en) | 2020-06-01 | 2023-04-05 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof |
EP4158005A1 (en) | 2020-06-01 | 2023-04-05 | ModernaTX, Inc. | Phenylalanine hydroxylase variants and uses thereof |
AU2021297248A1 (en) | 2020-06-23 | 2023-02-02 | Modernatx, Inc. | LNP compositions comprising mRNA therapeutics with extended half-life |
CN114206463A (en) | 2020-06-30 | 2022-03-18 | 苏州艾博生物科技有限公司 | Lipid compounds and lipid nanoparticle compositions |
CN116710079A (en) | 2020-07-24 | 2023-09-05 | 斯特兰德生物科技公司 | Lipid nanoparticles comprising modified nucleotides |
CN114391008B (en) | 2020-08-20 | 2024-05-03 | 苏州艾博生物科技有限公司 | Lipid compounds and lipid nanoparticle compositions |
WO2022104131A1 (en) | 2020-11-13 | 2022-05-19 | Modernatx, Inc. | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis |
US20230414516A1 (en) | 2020-11-16 | 2023-12-28 | BioNTech SE | Enhanced formulation stabilization and improved lyophilization processes |
US20240166707A1 (en) | 2021-01-08 | 2024-05-23 | Strand Therapeutics Inc. | Expression constructs and uses thereof |
WO2022152109A2 (en) | 2021-01-14 | 2022-07-21 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compounds and lipid nanoparticle compositions |
CN116615472A (en) | 2021-01-14 | 2023-08-18 | 苏州艾博生物科技有限公司 | Polymer conjugated lipid compounds and lipid nanoparticle compositions |
CA3210878A1 (en) | 2021-02-12 | 2022-08-18 | Modernatx, Inc. | Lnp compositions comprising payloads for in vivo therapy |
JP2024512026A (en) | 2021-03-24 | 2024-03-18 | モデルナティエックス インコーポレイテッド | Lipid nanoparticles and polynucleotide encoding ornithine transcarbamylase for the treatment of ornithine transcarbamylase deficiency |
WO2022204380A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof |
WO2022204369A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia |
WO2022204371A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof |
WO2022204390A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof |
WO2022212710A1 (en) | 2021-03-31 | 2022-10-06 | Modernatx, Inc. | PURIFICATION AND RECYCLING OF mRNA NUCLEOTIDE CAPS |
AU2022249357A1 (en) | 2021-04-01 | 2023-10-12 | Modernatx, Inc. | Methods for identification and ratio determination of rna species in multivalent rna compositions |
WO2022234416A1 (en) | 2021-05-03 | 2022-11-10 | Pfizer Inc. | Vaccination against pneumoccocal and covid-19 infections |
EP4333880A1 (en) | 2021-05-03 | 2024-03-13 | Pfizer Inc. | Immunogenic composition against influenza |
CA3218544A1 (en) | 2021-05-03 | 2022-11-10 | Pfizer Inc. | Vaccination against bacterial and betacoronavirus infections |
WO2022246020A1 (en) | 2021-05-19 | 2022-11-24 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia |
AU2022281746A1 (en) | 2021-05-24 | 2023-09-14 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compounds and lipid nanoparticle compositions |
WO2022266083A2 (en) | 2021-06-15 | 2022-12-22 | Modernatx, Inc. | Engineered polynucleotides for cell-type or microenvironment-specific expression |
WO2022271776A1 (en) | 2021-06-22 | 2022-12-29 | Modernatx, Inc. | Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome |
WO2023287751A1 (en) | 2021-07-12 | 2023-01-19 | Modernatx, Inc. | Polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits for the treatment of propionic acidemia |
WO2023009499A1 (en) | 2021-07-27 | 2023-02-02 | Modernatx, Inc. | Polynucleotides encoding glucose-6-phosphatase for the treatment of glycogen storage disease type 1a (gsd1a) |
WO2023056044A1 (en) | 2021-10-01 | 2023-04-06 | Modernatx, Inc. | Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease |
CN116064598B (en) | 2021-10-08 | 2024-03-12 | 苏州艾博生物科技有限公司 | Nucleic acid vaccine for coronavirus |
AU2022361755A1 (en) | 2021-10-08 | 2024-04-04 | Pfizer Inc. | Immunogenic lnp compositions and methods thereof |
AR127312A1 (en) | 2021-10-08 | 2024-01-10 | Suzhou Abogen Biosciences Co Ltd | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS |
AU2022358824A1 (en) | 2021-10-08 | 2024-04-11 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compounds and lipid nanoparticle compositions |
WO2023077170A1 (en) | 2021-11-01 | 2023-05-04 | Modernatx, Inc. | Polynucleotides encoding integrin beta-6 and methods of use thereof |
WO2023092060A1 (en) | 2021-11-18 | 2023-05-25 | Cornell University | Microrna-dependent mrna switches for tissue-specific mrna-based therapies |
WO2023111907A1 (en) | 2021-12-17 | 2023-06-22 | Pfizer Inc. | Polynucleotide compositions and uses thereof |
TW202345864A (en) | 2022-02-18 | 2023-12-01 | 美商現代公司 | Mrnas encoding checkpoint cancer vaccines and uses thereof |
WO2023183909A2 (en) | 2022-03-25 | 2023-09-28 | Modernatx, Inc. | Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia |
WO2023196399A1 (en) | 2022-04-06 | 2023-10-12 | Modernatx, Inc. | Lipid nanoparticles and polynucleotides encoding argininosuccinate lyase for the treatment of argininosuccinic aciduria |
WO2023201294A1 (en) | 2022-04-14 | 2023-10-19 | Modernatx, Inc. | Rna polymerase variants |
WO2023212618A1 (en) | 2022-04-26 | 2023-11-02 | Strand Therapeutics Inc. | Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof |
WO2023215498A2 (en) | 2022-05-05 | 2023-11-09 | Modernatx, Inc. | Compositions and methods for cd28 antagonism |
WO2024026254A1 (en) | 2022-07-26 | 2024-02-01 | Modernatx, Inc. | Engineered polynucleotides for temporal control of expression |
WO2024026490A1 (en) | 2022-07-28 | 2024-02-01 | Sqz Biotechnologies Company | Polynucleotides encoding linked antigens and uses thereof |
WO2024037578A1 (en) | 2022-08-18 | 2024-02-22 | Suzhou Abogen Biosciences Co., Ltd. | Composition of lipid nanoparticles |
WO2024057209A1 (en) | 2022-09-15 | 2024-03-21 | Pfizer Inc. | Coaxial flow device for nanoparticle preparation and manufacturing equipment including such device |
WO2024084397A1 (en) | 2022-10-19 | 2024-04-25 | Pfizer Inc. | Vaccination against pneumoccocal and covid-19 infections |
WO2024097639A1 (en) | 2022-10-31 | 2024-05-10 | Modernatx, Inc. | Hsa-binding antibodies and binding proteins and uses thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6060456A (en) * | 1993-11-16 | 2000-05-09 | Genta Incorporated | Chimeric oligonucleoside compounds |
AU687492B2 (en) * | 1993-11-16 | 1998-02-26 | Genta Incorporated | Synthetic oligomers having phosphonate internucleosidyl linkages of undefined chirality mixed with non-phosphonate internucleosidyl linkages |
US7074596B2 (en) * | 2002-03-25 | 2006-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of anti-reverse mRNA cap analogues |
US7368439B2 (en) * | 2005-06-15 | 2008-05-06 | Bar - Ilan University | Dinucleoside poly(borano)phosphate derivatives and uses thereof |
-
2008
- 2008-06-06 PL PL385388A patent/PL215513B1/en unknown
-
2009
- 2009-06-04 PL PL09759412T patent/PL2297175T3/en unknown
- 2009-06-04 EP EP09759412.1A patent/EP2297175B1/en active Active
- 2009-06-04 US US12/996,243 patent/US8519110B2/en active Active
- 2009-06-04 ES ES09759412T patent/ES2425781T3/en active Active
- 2009-06-04 WO PCT/US2009/046249 patent/WO2009149253A2/en active Application Filing
- 2009-06-04 JP JP2011512643A patent/JP5715560B2/en active Active
- 2009-06-04 AU AU2009256131A patent/AU2009256131B2/en active Active
- 2009-06-04 CA CA2727091A patent/CA2727091C/en active Active
Non-Patent Citations (2)
Title |
---|
None |
See also references of EP2297175A4 |
Cited By (183)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9447164B2 (en) | 2010-08-06 | 2016-09-20 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US9181319B2 (en) | 2010-08-06 | 2015-11-10 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US9937233B2 (en) | 2010-08-06 | 2018-04-10 | Modernatx, Inc. | Engineered nucleic acids and methods of use thereof |
US10064959B2 (en) | 2010-10-01 | 2018-09-04 | Modernatx, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US9334328B2 (en) | 2010-10-01 | 2016-05-10 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US9657295B2 (en) | 2010-10-01 | 2017-05-23 | Modernatx, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US9950068B2 (en) | 2011-03-31 | 2018-04-24 | Modernatx, Inc. | Delivery and formulation of engineered nucleic acids |
US10898574B2 (en) | 2011-03-31 | 2021-01-26 | Modernatx, Inc. | Delivery and formulation of engineered nucleic acids |
US11911474B2 (en) | 2011-03-31 | 2024-02-27 | Modernatx, Inc. | Delivery and formulation of engineered nucleic acids |
US10751386B2 (en) | 2011-09-12 | 2020-08-25 | Modernatx, Inc. | Engineered nucleic acids and methods of use thereof |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US10022425B2 (en) | 2011-09-12 | 2018-07-17 | Modernatx, Inc. | Engineered nucleic acids and methods of use thereof |
US9428535B2 (en) | 2011-10-03 | 2016-08-30 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US9295689B2 (en) | 2011-12-16 | 2016-03-29 | Moderna Therapeutics, Inc. | Formulation and delivery of PLGA microspheres |
US9271996B2 (en) | 2011-12-16 | 2016-03-01 | Moderna Therapeutics, Inc. | Formulation and delivery of PLGA microspheres |
US9216205B2 (en) | 2012-04-02 | 2015-12-22 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding granulysin |
US9095552B2 (en) | 2012-04-02 | 2015-08-04 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding copper metabolism (MURR1) domain containing 1 |
US9782462B2 (en) | 2012-04-02 | 2017-10-10 | Modernatx, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
US9192651B2 (en) | 2012-04-02 | 2015-11-24 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
US10385106B2 (en) | 2012-04-02 | 2019-08-20 | Modernatx, Inc. | Modified polynucleotides for the production of secreted proteins |
US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
US9221891B2 (en) | 2012-04-02 | 2015-12-29 | Moderna Therapeutics, Inc. | In vivo production of proteins |
US9220792B2 (en) | 2012-04-02 | 2015-12-29 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding aquaporin-5 |
US9220755B2 (en) | 2012-04-02 | 2015-12-29 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders |
US9233141B2 (en) | 2012-04-02 | 2016-01-12 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders |
US9255129B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding SIAH E3 ubiquitin protein ligase 1 |
US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
US9114113B2 (en) | 2012-04-02 | 2015-08-25 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding citeD4 |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9107886B2 (en) | 2012-04-02 | 2015-08-18 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding basic helix-loop-helix family member E41 |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9301993B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding apoptosis inducing factor 1 |
US8999380B2 (en) | 2012-04-02 | 2015-04-07 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
US10577403B2 (en) | 2012-04-02 | 2020-03-03 | Modernatx, Inc. | Modified polynucleotides for the production of secreted proteins |
US9089604B2 (en) | 2012-04-02 | 2015-07-28 | Moderna Therapeutics, Inc. | Modified polynucleotides for treating galactosylceramidase protein deficiency |
US9149506B2 (en) | 2012-04-02 | 2015-10-06 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding septin-4 |
US9061059B2 (en) | 2012-04-02 | 2015-06-23 | Moderna Therapeutics, Inc. | Modified polynucleotides for treating protein deficiency |
US9050297B2 (en) | 2012-04-02 | 2015-06-09 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding aryl hydrocarbon receptor nuclear translocator |
US10703789B2 (en) | 2012-04-02 | 2020-07-07 | Modernatx, Inc. | Modified polynucleotides for the production of secreted proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9587003B2 (en) | 2012-04-02 | 2017-03-07 | Modernatx, Inc. | Modified polynucleotides for the production of oncology-related proteins and peptides |
US9814760B2 (en) | 2012-04-02 | 2017-11-14 | Modernatx, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
US9828416B2 (en) | 2012-04-02 | 2017-11-28 | Modernatx, Inc. | Modified polynucleotides for the production of secreted proteins |
US9827332B2 (en) | 2012-04-02 | 2017-11-28 | Modernatx, Inc. | Modified polynucleotides for the production of proteins |
US9597380B2 (en) | 2012-11-26 | 2017-03-21 | Modernatx, Inc. | Terminally modified RNA |
CN103254260A (en) * | 2013-02-07 | 2013-08-21 | 江西科技师范大学 | Method for synthesizing symmetric dinucleoside diphosphate disodium salt from nucleoside hydrogen phosphite monoester |
CN103254260B (en) * | 2013-02-07 | 2015-11-11 | 江西科技师范大学 | The method of symmetric double nucleoside diphosphate disodium salt is synthesized by nucleosides hydrogen monophosphite |
WO2014152211A1 (en) | 2013-03-14 | 2014-09-25 | Moderna Therapeutics, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
US11377470B2 (en) | 2013-03-15 | 2022-07-05 | Modernatx, Inc. | Ribonucleic acid purification |
WO2014152540A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
EP3578663A1 (en) * | 2013-03-15 | 2019-12-11 | ModernaTX, Inc. | Manufacturing methods for production of rna transcripts |
US10590161B2 (en) | 2013-03-15 | 2020-03-17 | Modernatx, Inc. | Ion exchange purification of mRNA |
US10138507B2 (en) | 2013-03-15 | 2018-11-27 | Modernatx, Inc. | Manufacturing methods for production of RNA transcripts |
US10077439B2 (en) | 2013-03-15 | 2018-09-18 | Modernatx, Inc. | Removal of DNA fragments in mRNA production process |
EP2971033A4 (en) * | 2013-03-15 | 2016-11-16 | Moderna Therapeutics Inc | Manufacturing methods for production of rna transcripts |
US11845772B2 (en) | 2013-03-15 | 2023-12-19 | Modernatx, Inc. | Ribonucleic acid purification |
US10858647B2 (en) | 2013-03-15 | 2020-12-08 | Modernatx, Inc. | Removal of DNA fragments in mRNA production process |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
US11027025B2 (en) | 2013-07-11 | 2021-06-08 | Modernatx, Inc. | Compositions comprising synthetic polynucleotides encoding CRISPR related proteins and synthetic sgRNAs and methods of use |
WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
WO2015034928A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
US10815291B2 (en) | 2013-09-30 | 2020-10-27 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
US10385088B2 (en) | 2013-10-02 | 2019-08-20 | Modernatx, Inc. | Polynucleotide molecules and uses thereof |
US10323076B2 (en) | 2013-10-03 | 2019-06-18 | Modernatx, Inc. | Polynucleotides encoding low density lipoprotein receptor |
WO2015051214A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
WO2015101416A1 (en) | 2013-12-30 | 2015-07-09 | Curevac Gmbh | Methods for rna analysis |
EP3540060A1 (en) | 2013-12-30 | 2019-09-18 | CureVac AG | Methods for rna analysis |
EP3521456A1 (en) | 2014-06-10 | 2019-08-07 | CureVac AG | Methods and means for enhancing rna production |
WO2015188933A1 (en) | 2014-06-10 | 2015-12-17 | Curevac Ag | Methods and means for enhancing rna production |
US10286086B2 (en) | 2014-06-19 | 2019-05-14 | Modernatx, Inc. | Alternative nucleic acid molecules and uses thereof |
US10407683B2 (en) | 2014-07-16 | 2019-09-10 | Modernatx, Inc. | Circular polynucleotides |
EP4159741A1 (en) | 2014-07-16 | 2023-04-05 | ModernaTX, Inc. | Method for producing a chimeric polynucleotide encoding a polypeptide having a triazole-containing internucleotide linkage |
CN107223128A (en) * | 2014-12-16 | 2017-09-29 | 诺华股份有限公司 | The nucleic acid molecules that end is capped |
WO2016098028A1 (en) | 2014-12-16 | 2016-06-23 | Novartis Ag | End capped nucleic acid molecules |
EP3904366A1 (en) | 2014-12-16 | 2021-11-03 | Novartis AG | End capped nucleic acid molecules |
US10676499B2 (en) | 2014-12-16 | 2020-06-09 | Novartis Ag | 3′ end caps, 5′ end caps and combinations thereof for therapeutic RNA |
US11466048B2 (en) | 2014-12-16 | 2022-10-11 | Novartis Ag | 3′ end caps, 5′ end caps and combinations thereof for therapeutic RNA |
CN111848712A (en) * | 2014-12-16 | 2020-10-30 | 诺华股份有限公司 | End-capped nucleic acid molecules |
EP3173092A2 (en) | 2015-04-22 | 2017-05-31 | CureVac AG | Rna containing composition for treatment of tumor diseases |
WO2016170176A1 (en) | 2015-04-22 | 2016-10-27 | Curevac Ag | Rna containing composition for treatment of tumor diseases |
EP3603661A2 (en) | 2015-04-22 | 2020-02-05 | CureVac AG | Rna containing composition for treatment of tumor diseases |
EP3326641A1 (en) | 2015-04-22 | 2018-05-30 | CureVac AG | Rna containing composition for treatment of tumor diseases |
US11834651B2 (en) | 2015-05-29 | 2023-12-05 | CureVac Manufacturing GmbH | Method for producing and purifying RNA, comprising at least one step of tangential flow filtration |
EP4239080A2 (en) | 2015-07-01 | 2023-09-06 | CureVac Manufacturing GmbH | Method for analysis of an rna molecule |
US11434486B2 (en) | 2015-09-17 | 2022-09-06 | Modernatx, Inc. | Polynucleotides containing a morpholino linker |
US10428106B2 (en) | 2015-10-16 | 2019-10-01 | Modernatx, Inc. | Phosphate replacement mRNA cap analogs |
US10570388B2 (en) | 2015-10-16 | 2020-02-25 | Modernatx, Inc. | Phosphate replacement MRNA cap analogs |
WO2017066789A1 (en) * | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Mrna cap analogs with modified sugar |
EP4086269A1 (en) * | 2015-10-16 | 2022-11-09 | ModernaTX, Inc. | Mrna cap analogs with modified phosphate linkage |
WO2017066781A1 (en) * | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Mrna cap analogs with modified phosphate linkage |
US11866754B2 (en) | 2015-10-16 | 2024-01-09 | Modernatx, Inc. | Trinucleotide mRNA cap analogs |
US10563195B2 (en) | 2015-10-16 | 2020-02-18 | Modernatx, Inc. | Phosphate replacement mRNA cap analogs |
WO2017109161A1 (en) | 2015-12-23 | 2017-06-29 | Curevac Ag | Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof |
US11248223B2 (en) | 2015-12-23 | 2022-02-15 | Curevac Ag | Method of RNA in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof |
WO2017130151A1 (en) * | 2016-01-29 | 2017-08-03 | Uniwersytet Warszawski | 5'-phosphorothiolate mrna 5'-end (cap) analogs, mrna comprising the same, method of obtaining and uses thereof |
CN109071589A (en) * | 2016-01-29 | 2018-12-21 | 华沙大学 | 5 ' -5 '-the end thiophosphate mRNA (cap) analogs, the mRNA comprising the analog, its preparation method and purposes |
EA038834B1 (en) * | 2016-01-29 | 2021-10-26 | Университет Варшавский | 5'-PHOSPHOROTHIOLATE mRNA 5'-END (CAP) ANALOGS, mRNA COMPRISING THE SAME, METHOD OF PREPARATION AND USE THEREOF |
US11066436B2 (en) | 2016-01-29 | 2021-07-20 | Uniwersytet Warszawski | 5′-phosphorothiolate mRNA 5′-end (cap) analogs, mRNA comprising the same, method of obtaining and uses thereof |
WO2017140345A1 (en) | 2016-02-15 | 2017-08-24 | Curevac Ag | Method for analyzing by-products of rna in vitro transcription |
US11920174B2 (en) | 2016-03-03 | 2024-03-05 | CureVac SE | RNA analysis by total hydrolysis and quantification of released nucleosides |
WO2017149139A1 (en) | 2016-03-03 | 2017-09-08 | Curevac Ag | Rna analysis by total hydrolysis |
EP3701959A1 (en) | 2016-03-21 | 2020-09-02 | BioNTech RNA Pharmaceuticals GmbH | Rna replicon for versatile and efficient gene expression |
WO2017162461A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Trans-replicating rna |
EP3964584A1 (en) | 2016-03-21 | 2022-03-09 | BioNTech SE | Trans-replicating rna |
EP4233898A2 (en) | 2016-05-04 | 2023-08-30 | CureVac SE | Influenza mrna vaccines |
WO2018033254A2 (en) | 2016-08-19 | 2018-02-22 | Curevac Ag | Rna for cancer therapy |
WO2018078053A1 (en) | 2016-10-26 | 2018-05-03 | Curevac Ag | Lipid nanoparticle mrna vaccines |
WO2018115507A2 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Henipavirus vaccine |
WO2018115527A2 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Mers coronavirus vaccine |
US11920148B2 (en) | 2017-02-22 | 2024-03-05 | Crispr Therapeutics Ag | Compositions and methods for gene editing |
EP4124340A1 (en) | 2017-06-21 | 2023-02-01 | New England Biolabs, Inc. | Use of thermostable rna polymerases to produce rnas having reduced immunogenicity |
WO2018236617A1 (en) | 2017-06-21 | 2018-12-27 | New England Biolabs, Inc. | Use of thermostable rna polymerases to produce rnas having reduced immunogenicity |
EP3424524A2 (en) | 2017-07-04 | 2019-01-09 | CureVac AG | Cancer rna-vaccine |
WO2019008001A1 (en) | 2017-07-04 | 2019-01-10 | Curevac Ag | Novel nucleic acid molecules |
WO2019038332A1 (en) | 2017-08-22 | 2019-02-28 | Curevac Ag | Bunyavirales vaccine |
WO2019053003A1 (en) | 2017-09-13 | 2019-03-21 | Biontech Rna Pharmaceuticals Gmbh | Method of enhancing rna expression in a cell |
EP4368702A2 (en) | 2017-09-13 | 2024-05-15 | BioNTech SE | Method of enhancing rna expression in a cell |
WO2019053012A1 (en) | 2017-09-13 | 2019-03-21 | Biontech Rna Pharmaceuticals Gmbh | Rna replicon for reprogramming somatic cells |
WO2019053056A1 (en) | 2017-09-13 | 2019-03-21 | Biontech Cell & Gene Therapies Gmbh | Rna replicon for expressing a t cell receptor or an artificial t cell receptor |
WO2019092153A1 (en) | 2017-11-08 | 2019-05-16 | Curevac Ag | Rna sequence adaptation |
WO2019115635A1 (en) | 2017-12-13 | 2019-06-20 | Curevac Ag | Flavivirus vaccine |
WO2019122371A1 (en) | 2017-12-21 | 2019-06-27 | Curevac Ag | Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna |
WO2019193183A2 (en) | 2018-04-05 | 2019-10-10 | Curevac Ag | Novel yellow fever nucleic acid molecules for vaccination |
EP4227319A1 (en) | 2018-04-17 | 2023-08-16 | CureVac SE | Novel rsv rna molecules and compositions for vaccination |
WO2020002525A1 (en) | 2018-06-27 | 2020-01-02 | Curevac Ag | Novel lassa virus rna molecules and compositions for vaccination |
WO2020072914A1 (en) | 2018-10-04 | 2020-04-09 | New England Biolabs, Inc. | Methods and compositions for increasing capping efficiency of transcribed rna |
US20200109425A1 (en) * | 2018-10-04 | 2020-04-09 | New England Biolabs, Inc. | Methods and Compositions for Increasing Capping Efficiency of Transcribed RNA |
US11072808B2 (en) | 2018-10-04 | 2021-07-27 | New England Biolabs, Inc. | Methods and compositions for increasing capping efficiency of transcribed RNA |
WO2020127959A1 (en) | 2018-12-21 | 2020-06-25 | Curevac Ag | Methods for rna analysis |
WO2020128031A2 (en) | 2018-12-21 | 2020-06-25 | Curevac Ag | Rna for malaria vaccines |
WO2020161342A1 (en) | 2019-02-08 | 2020-08-13 | Curevac Ag | Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases |
WO2020254535A1 (en) | 2019-06-18 | 2020-12-24 | Curevac Ag | Rotavirus mrna vaccine |
WO2021028439A1 (en) | 2019-08-14 | 2021-02-18 | Curevac Ag | Rna combinations and compositions with decreased immunostimulatory properties |
WO2021123332A1 (en) | 2019-12-20 | 2021-06-24 | Curevac Ag | Lipid nanoparticles for delivery of nucleic acids |
US11964011B2 (en) | 2020-02-04 | 2024-04-23 | CureVac SE | Coronavirus vaccine |
DE202021004123U1 (en) | 2020-02-04 | 2022-10-26 | Curevac Ag | Coronavirus Vaccine |
DE202021004130U1 (en) | 2020-02-04 | 2022-10-26 | Curevac Ag | Coronavirus Vaccine |
US11471525B2 (en) | 2020-02-04 | 2022-10-18 | Curevac Ag | Coronavirus vaccine |
WO2021156267A1 (en) | 2020-02-04 | 2021-08-12 | Curevac Ag | Coronavirus vaccine |
DE202021003575U1 (en) | 2020-02-04 | 2022-01-17 | Curevac Ag | Coronavirus Vaccine |
DE112021000012T5 (en) | 2020-02-04 | 2021-11-18 | Curevac Ag | Coronavirus vaccine |
EP4147717A1 (en) | 2020-02-04 | 2023-03-15 | CureVac SE | Coronavirus vaccine |
US11576966B2 (en) | 2020-02-04 | 2023-02-14 | CureVac SE | Coronavirus vaccine |
US11596686B2 (en) | 2020-02-04 | 2023-03-07 | CureVac SE | Coronavirus vaccine |
US11964012B2 (en) | 2020-02-04 | 2024-04-23 | CureVac SE | Coronavirus vaccine |
US11951185B2 (en) | 2020-04-22 | 2024-04-09 | BioNTech SE | RNA constructs and uses thereof |
US11779659B2 (en) | 2020-04-22 | 2023-10-10 | BioNTech SE | RNA constructs and uses thereof |
WO2021239880A1 (en) | 2020-05-29 | 2021-12-02 | Curevac Ag | Nucleic acid based combination vaccines |
WO2021245090A1 (en) | 2020-06-04 | 2021-12-09 | BioNTech SE | Rna replicon for versatile and efficient gene expression |
WO2022023559A1 (en) | 2020-07-31 | 2022-02-03 | Curevac Ag | Nucleic acid encoded antibody mixtures |
WO2022043551A2 (en) | 2020-08-31 | 2022-03-03 | Curevac Ag | Multivalent nucleic acid based coronavirus vaccines |
WO2022122689A1 (en) | 2020-12-09 | 2022-06-16 | BioNTech SE | Rna manufacturing |
WO2022135993A2 (en) | 2020-12-22 | 2022-06-30 | Curevac Ag | Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration |
US11918643B2 (en) | 2020-12-22 | 2024-03-05 | CureVac SE | RNA vaccine against SARS-CoV-2 variants |
WO2022137133A1 (en) | 2020-12-22 | 2022-06-30 | Curevac Ag | Rna vaccine against sars-cov-2 variants |
US11872280B2 (en) | 2020-12-22 | 2024-01-16 | CureVac SE | RNA vaccine against SARS-CoV-2 variants |
WO2022162027A2 (en) | 2021-01-27 | 2022-08-04 | Curevac Ag | Method of reducing the immunostimulatory properties of in vitro transcribed rna |
WO2022200575A1 (en) | 2021-03-26 | 2022-09-29 | Glaxosmithkline Biologicals Sa | Immunogenic compositions |
WO2022207862A2 (en) | 2021-03-31 | 2022-10-06 | Curevac Ag | Syringes containing pharmaceutical compositions comprising rna |
WO2022233880A1 (en) | 2021-05-03 | 2022-11-10 | Curevac Ag | Improved nucleic acid sequence for cell type specific expression |
WO2023006999A2 (en) | 2021-07-30 | 2023-02-02 | CureVac SE | Mrnas for treatment or prophylaxis of liver diseases |
WO2023007019A1 (en) | 2021-07-30 | 2023-02-02 | CureVac SE | Cap analogs having an acyclic linker to the guanine derivative nucleobase |
WO2023031392A2 (en) | 2021-09-03 | 2023-03-09 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine |
WO2023031394A1 (en) | 2021-09-03 | 2023-03-09 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids |
WO2023066875A1 (en) | 2021-10-18 | 2023-04-27 | BioNTech SE | Modified replicable rna and related compositions and their use |
WO2023066874A1 (en) | 2021-10-18 | 2023-04-27 | BioNTech SE | Methods for determining mutations for increasing modified replicable rna function and related compositions and their use |
WO2023139170A1 (en) | 2022-01-21 | 2023-07-27 | BioNTech SE | Analysis of rna molecules using catalytic nucleic acids |
WO2023138786A1 (en) | 2022-01-21 | 2023-07-27 | BioNTech SE | Analysis of rna molecules using catalytic nucleic acids |
WO2023144330A1 (en) | 2022-01-28 | 2023-08-03 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
WO2023166425A1 (en) | 2022-03-01 | 2023-09-07 | Crispr Therapeutics Ag | Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions |
WO2023180904A1 (en) | 2022-03-21 | 2023-09-28 | Crispr Therapeutics Ag | Methods and compositions for treating lipoprotein-related diseases |
WO2023213378A1 (en) | 2022-05-02 | 2023-11-09 | BioNTech SE | Replicon compositions and methods of using same for the treatment of diseases |
WO2023213783A1 (en) | 2022-05-02 | 2023-11-09 | BioNTech SE | Replicon compositions and methods of using same for the treatment of diseases |
WO2023227608A1 (en) | 2022-05-25 | 2023-11-30 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
WO2024018035A1 (en) | 2022-07-21 | 2024-01-25 | BioNTech SE | Multifunctional cells transiently expressing an immune receptor and one or more cytokines, their use and methods for their production |
WO2024017479A1 (en) | 2022-07-21 | 2024-01-25 | BioNTech SE | Multifunctional cells transiently expressing an immune receptor and one or more cytokines, their use and methods for their production |
WO2024056856A1 (en) | 2022-09-15 | 2024-03-21 | BioNTech SE | Systems and compositions comprising trans-amplifying rna vectors with mirna |
WO2024068545A1 (en) | 2022-09-26 | 2024-04-04 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
DE202023106198U1 (en) | 2022-10-28 | 2024-03-21 | CureVac SE | Nucleic acid-based vaccine |
WO2024089638A1 (en) | 2022-10-28 | 2024-05-02 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine |
Also Published As
Publication number | Publication date |
---|---|
US20110092574A1 (en) | 2011-04-21 |
WO2009149253A3 (en) | 2010-03-25 |
PL2297175T3 (en) | 2014-01-31 |
AU2009256131B2 (en) | 2013-05-30 |
US8519110B2 (en) | 2013-08-27 |
EP2297175A4 (en) | 2011-06-15 |
JP2011522542A (en) | 2011-08-04 |
AU2009256131A1 (en) | 2009-12-10 |
JP5715560B2 (en) | 2015-05-07 |
PL385388A1 (en) | 2009-12-07 |
EP2297175B1 (en) | 2013-08-07 |
CA2727091A1 (en) | 2009-12-10 |
PL215513B1 (en) | 2013-12-31 |
CA2727091C (en) | 2017-05-09 |
ES2425781T3 (en) | 2013-10-17 |
EP2297175A2 (en) | 2011-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2727091C (en) | Mrna cap analogs | |
CA2692906C (en) | Synthesis and use of anti-reverse phosphorothioate analogs of the messenger rna cap | |
Jemielity et al. | Synthetic mRNA cap analogs with a modified triphosphate bridge–synthesis, applications and prospects | |
JP2022538784A (en) | Reagents and methods for replication, transcription and translation in semi-synthetic organisms | |
JP7144050B2 (en) | 5'-Phosphorothiolate mRNA 5'-Terminal (Cap) Analogs, mRNAs Containing Them, Methods of Obtaining Them and Methods of Using Them | |
Rydzik et al. | Synthetic dinucleotide mRNA cap analogs with tetraphosphate 5′, 5′ bridge containing methylenebis (phosphonate) modification | |
JP2023513756A (en) | Novel mRNA 5'-terminal cap analogs modified within the phosphate residue, RNA molecules incorporating same, uses thereof, and methods of synthesizing RNA molecules or peptides | |
Strenkowska et al. | Towards mRNA with superior translational activity: synthesis and properties of ARCA tetraphosphates with single phosphorothioate modifications | |
Kozarski et al. | Towards superior mRNA caps accessible by click chemistry: synthesis and translational properties of triazole-bearing oligonucleotide cap analogs | |
US10696709B2 (en) | Phosphotriazole MRNA 5′-end cap analogs, composition comprising the same, RNA molecule incorporating the same, uses thereof and method of synthesizing RNA molecule, protein or peptide | |
KR102097053B1 (en) | Process for preparing phosphate compound bearing isotope | |
KR20240035752A (en) | Method for concentrating circular polyribonucleotides | |
JP2005046073A (en) | Method of rna transcription and/or amplification using modified nucleic acid | |
PL214850B1 (en) | RNA molecule, the manner of obtaining of RNA and the manner of obtaining of peptites and proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09759412 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009256131 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011512643 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12996243 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2727091 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009759412 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2009256131 Country of ref document: AU Date of ref document: 20090604 Kind code of ref document: A |